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Summary 
 
Obesity has reached pandemic proportions, and is associated with several co-morbidities like 
cardiovascular disorders, hypertension, dyslipidemia, and Type 2 diabetes mellitus. The dysregulated 
adipose tissue metabolism in obesity leads to an altered adipokine secretion, which can influence energy 
homeostasis, promote insulin resistance, as well as provide pro-tumorigenic signals to tumor cells. We 
investigated the link between obesity, and the progression of pancreatic ductal adenocarcinoma (PDAC). 
Although, obesity has been associated with a poor prognosis in PDAC, the underlying mechanisms are 
unclear.  
 
At first, we used adipose tissue specific knockout of TBLR1 (ATKO) mice as a model of obesity, to 
investigate if the transcriptional inactivation of the transcriptional co-factor Transducin beta like related 
1 (TBLR1) promoted PDAC progression. Although, subcutaneous (SC) Panc02 tumors grew significantly 
larger in the ATKO mice, compared to wt littermates, histological examination of the tumors did not 
reveal increased proliferation, or adipocyte infiltration in the tumors from ATKO mice. Also, gene 
expression analysis in tumors from wt and ATKO mice did not reveal any significantly differentially 
regulated genes. Finally, in vivo effects could not be validated by treating PDAC cells with conditioned 
media (CM) generated from primary adipocytes of ATKO mice, or from Tblr1 knockdown 3T3-L1 
adipocytes.  Therefore, we could not establish a robust link between the absence of Tblr1 in the adipose 
tissue, to PDAC progression. 
 
Using in vitro assays, we demonstrated that adipocyte-conditioned media (ACM) from differentiated 
3T3-L1 adipocytes, but not fibroblasts, promoted PDAC cell viability, proliferation, migration, and 
invasion in vitro. Therefore, we hypothesized that secreted factors from adipocytes mediate pro-
tumorigenic effects on PDAC. Previously it was shown by our group that SC Panc02 tumors grew 
significantly larger in db/db mice, compared to wt mice. Microarray analysis of the SC inguinal white 
adipose tissue (iWAT) of db/db, and wt mice identified ob gene encoding leptin as one of the most 
significantly differentially regulated genes. Although, recombinant leptin did not affect proliferation, or 
migration of PDAC cell monolayer cultures, it increased the invasion of BxPC3 spheroids through collagen 
matrix. Most importantly, leptin increased the viability of PDAC cells upon treatment with gemcitabine. 
Thus, we hypothesized that leptin improves the chemo-resistance of PDAC cells to gemcitabine. 
However, knockdown of Lepr in PDAC cells did not affect proliferation, and viability upon gemcitabine 
treatment. Also, Lepr kd Panc02 tumors implanted subcutaneously into wt mice, displayed similar 
chemo-sensitivity to gemcitabine treatment in vivo, as compared to wt Panc02 tumors. Finally, 
pharmacological inhibition of human LEPR with anti-LEPR antibody did not affect the chemo-resistance 
of PDAC cells to gemcitabine.  
 
In conclusion, although there was a strong effect of ACM from 3T3-L1 cells on PDAC growth in vitro, the 
effects could not be attributed entirely to leptin. Further investigation is required to identify the secreted 
factors from dysregulated adipocytes which could play a potential pro-tumorigenic role on PDAC 
progression, thus providing a link between obesity and PDAC development. 
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Zusammenfassung 
 
Fettleibigkeit, welches pandemische Ausmasse erreicht, geht mit mehreren Erkranungen, wie 
Kardiovaskuläre-, Bluthochdruck, erhöhte Cholesterin Level und Type 2 Diabetes, einher. Der durch 
Fettleibigkeit gestörte Fettgewebsmetabolismus führt zu einer geänderten Sekretion von Adipokinen, 
welche die Energie-Homeostase beeinflussen, Insulinresistenz fördern und pro-tumorigene Wirkung auf 
Krebszellen haben können. Wir haben den funktionellen Zusammenhang zwischen Fettleibigkeit und der 
Entwicklung des pankreatischen duktalen Adenokarzinoms (PDAC) untersucht. Obwohl Fettleibigkeit mit 
einer schlechteren Prognose für PDAC assoziiert ist, sind die zugrundeliegenden Mechanismen noch 
relativ unbekannt. 
 
Wir nutzten die Fettgewebsspezifische Knockout Maus für TBLR1 (ATKO) als Modelorganismus für 
Fettleibigkeit, um zu untersuchen ob die transkriptionelle Inaktivierung des Transkriptionellen Ko-
Faktors Transducin Beta like related 1 (TBLR1) PDAC Entwicklung fördert. Obwohl subkutan implantierte 
(SK) Panc02 Tumore von ATKO Mäusen signifikant erhöhtes Wachstum gegenüber Wildtyp (WT) 
Wurfgeschwistern aufzeigten, konnten nach histologischer Analyse keine erhöhte Proliferation oder 
Adipozyten Infiltration in die Tumore von ATKO Mäusen gemessen werden. Genexpressionsanalysen 
von Tumoren aus WT und ATKO Mäusen zeigte keine signifikant differentiell regulierten Gene. Es 
konnten die in vivo Effekte auch nicht validiert werden, indem PDAC Zellen mit Konditionertes Medium 
von primären Adipozyten der ATKO Mäuse oder Tblr1 knockdown 3T3-L1 Adipozyten behandelt wurden. 
Insofern konnte keine Verbindung zwischen dem Fehlen von Tblr1 im Fettgewebe und PDAC Entwicklung 
gefunden werden. 
 
In in vitro Assays konnte demonstriert werden, dass Adipozyten-konditioniertes Medium von 
differenzierten 3T3-L1 Adipozyten, aber nicht Fibroblasten, PDAC Zellviabilität, Proliferation, Migration 
und Invasion bewirkt. Daher wurde die Hypothese aufgestellt, dass sekretierte Faktoren von Adipozyten 
die pro-tumorigenen Effekte auf PDAC bewirken. Kürzlich wurde von unserem Labor gezeigt, dass SK 
Panc02 Tumore in db/db Mäusen signifikant grösseres Wachstum aufzeigen als in WT Mäusen. 
Microarray Analysen des SK inguinalen weissen Fettgewebes (iWAT) der db/db und WT Mäuse 
identifizierte das ob Gen, welches für Leptin kodiert, als eines der am höchsten signifikant differentiell 
exprimierten Gene. Obwohl rekombinantes Leptin keine Proliferation oder Migration von PDAC Zellen 
in Einzelschichten wachsend bewirkte, erhöhte es jedoch die Invasion von BxPC3 Spheroiden durch eine 
Kollagen Matrix. Interessanterweise erhöhte Leptin die Viabilität von Gemcitabine behandelten PDAC 
Zellen. Daher wurde hypothetisiert, dass Leptin die Chemoresistenz von PDAC Zellen gegenüber 
Gemcitabine erhöht. Jedoch bewirkte der Leptinrezeptor (Lepr) knockdown in PDAC Zellen keine 
Änderung in Proliferation oder Viabilität bei Gemcitabine Behandlung. Überdies zeigten SK in WT Mäuse 
implantierte Lepr knockdown Zellen ähnliche Sensitivität gegenüber Gemcitabine im Vergleich zu 
Kontroll Panc02 Tumoren. Auch pharmakologische Inhibierung des humanen LEPR mit einem anti-LEPR 
Antikörper hatte keinen Effekt auf Chemoresistenz der PDAC Zellen gegenüber Gemcitabine. 
 
Zusammenfassend kann gesagt werden, dass, obwohl ein starker Effekt von AKM der 3T3-L1 Zellen auf 
PDAC Wachstum in vitro festgestellt werden konnte, konnten diese Effekte nicht vollständig auf Leptin 
zurückgeführt werden. Weitere Untersuchungen sind nötig, um die Sekretierten Faktoren von 
dysregulierten Adipozyten zu identifizieren, welche eine potentiell pro-tumorigene Rolle bei der PDAC 
Entwicklung spielen um damit einen Zusammenhang zwischen Fettleibigkeit und PDAC Entwicklung 
herzustellen. 
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1 INTRODUCTION 
1.1 Metabolic syndrome and obesity: A Global Pandemic 
1.1.1 Metabolic syndrome: Definition, and epidemiology 
 
The term “Metabolic Syndrome” (MetS), was first used by Haller and Hanefeld in 1975 [1]. MetS is defined 
by the clustering of several interconnected biochemical, clinical, and metabolic factors, like central 
obesity, insulin resistance, hypertension, and dyslipidemia, that synergistically increase the risk for 
developing cardiovascular disease (CVD), and type 2 diabetes mellitus (T2DM) [1], [2].  
 
The global occurrence of MetS ranges between 10% to as much as 84% based on the geographical 
location, age, gender, and ethnicity of the population being examined (WHO fact sheet No. 311, 2015). 
Greater socio-economic status, reduced physical activity, and high body mass index (BMI) were 
significantly correlated with MetS [2]. Overweight, and obesity, are defined as having a BMI ≥ 25 kg/m², 
and ≥ 30 kg/m² respectively, and have reached epidemic proportions. Globally, more than 1.9 billion 
adults aged 18 and above were found to be overweight in 2014, of which 600 million were obese (WHO 
fact sheet No. 311, 2015). The number of obese individuals has more than doubled between 1980 and 
2014 (WHO fact sheet No. 311, 2015). Although considered as a disease of affluence, obesity is now 
spreading to poorer nations and is a growing threat to the developing world [3]. Currently, bariatric 
surgery is the best treatment option available for severely obese patients [4]. Therefore, there is a huge 
need for improved pharmacological treatment strategies to address the global obesity epidemic [5]. 
Better understanding of the molecular mechanisms that regulate obesity, and its influence on other 
organs is necessary to develop novel therapeutics for this condition [6].  
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Figure 1: Global Database on Body Mass Index. Mean body mass index trends (kg/m2), ages 18+, 2014 (age 
standardized estimate). Source: WHO (http://apps.who.int/bmi/index.jsp) 
 
1.1.2 Obesity is fundamental for development of metabolic syndrome 
 
The underlying cause of obesity is a sustained imbalance between energy intake and expenditure (WHO 
fact sheet No. 311, 2015), [5]. Consumption of calorie rich diet, in combination with a sedentary lifestyle 
has contributed greatly to the epidemic of obesity. Although dyslipidemia, hypertension, hyperglycemia, 
and a chronic pro-inflammatory state are well-accepted risk factors for the development of MetS, 
abdominal obesity, and insulin resistance (IR) are considered as the underlying causes [7]. 
 
The mechanisms causing MetS are a subject of ongoing research due to the complex interaction between 
different metabolic, genetic, and environmental factors [8]. It is known that overweight and obesity result 
in hypertrophic expansion of the adipose tissue, particularly the visceral fat depot [9]. These hypertrophic 
abdominal adipocytes contribute to increased amounts of circulating free fatty acids (FFAs) [10]. FFAs 
have been known to inhibit insulin mediated glucose transport and/or phosphorylation, and contribute 
to insulin resistance [11]. The increased amounts of FFAs thus cause a state of peripheral muscle insulin 
resistance, and hyperglycemia. In order to compensate for the reduced peripheral insulin action, and 
achieve a normoglycemic state, more insulin is secreted which results in hyperinsulinemia, and ultimately 
-cell hypertrophy [12], [13]. Hence, obesity associated insulin resistance is one of the key mechanisms 
causing MetS. 
 
1.2 Adipose tissue in energy homeostasis and metabolic disorders 
1.2.1 Classification of adipose tissue, and its role in metabolic homeostasis 
 
Historically, the adipose tissue was considered merely as an organ responsible for storing energy, and 
hence did not gain much attention from researchers. However, the global rise in obesity has led to a 
renewed interest in understanding the role of adipose tissue in the regulation of systemic energy 
homeostasis. Adipose tissue is classified into two main categories in humans, the white adipose tissue 
(WAT), and the brown adipose tissue (BAT). Based on its anatomy, the WAT is further classified into two 
depots namely, the subcutaneous WAT, and the visceral WAT. The adipocytes and progenitor cells from 
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distinct depots differ in their proliferative capacities, developmental origin, and response to hormonal 
stimuli [14]. The primary function of the WAT is to store energy, and to provide insulation. On the other 
hand, the BAT is rich in mitochondria and is distinguished by its expression of the uncoupling protein-1 
(UCP1) which is involved in cold induced thermogenesis [15].  
  
Adipose tissue is composed of different cell types, such as the mature adipocytes, and the stromal 
vascular fraction consisting of fibroblasts, precursor cells, immune cells, and blood cells. The adipocytes 
secrete a variety of proteins called adipokines, which contribute to the regulation of systemic energy 
metabolism by their paracrine and endocrine effects on multiple other organs like brain, liver, muscle, 
vasculature, and pancreas [16], [17]. 
 
 
 
 
 
Fig. 2: Classification and function of adipose tissue in humans and mice. (A) In humans, BAT is located near the 
shoulders and ribs, and is thought to regulate body temperature. The brown adipocytes are rich in mitochondria 
and express UCP-1. The visceral WAT surrounds the intra-abdominal organs, and the subcutaneous WAT is present 
under the skin. Both the white, and brown adipocytes release several adipokines, which regulate whole-body energy 
homeostasis. Obesity and MetS are associated with the dysregulation of the visceral WAT. (B) In adult mice, the 
BAT is distinct and easily identifiable. The WAT depot consists of pair of adipose tissue surrounding the gonads (peri-
gonadal), and are used as a model of visceral WAT. The subcutaneous inguinal depots found at the back of the hind 
limbs serve as a model of subcutaneous WAT (Adapted from [15]).  
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1.2.2 Adipose tissue dysregulation in obesity  
 
Adipocytes function to store the surplus calories in the form of triglycerides within lipid droplets, and 
release free fatty acids upon energy deficit. When challenged with over nutrition, the adipocytes adapt 
and expand in order to prevent lipid spill over into other organs. This is achieved either by  increasing 
the size of pre-existing adipocytes (hypertrophy), or by increasing the number of adipocytes 
(hyperplasia) [18]. The number of adipocytes stays constant in adults, and is determined during 
childhood and adolescence [19]. Terminally differentiated adipocytes in adults, adapt to positive energy 
balance predominantly by hypertrophic expansion [19]. The expandability of hypertrophic adipocytes 
is not unlimited, and is dependent on several factors like the formation of new blood vessels 
(angiogenesis), and the remodeling of matrix components [20]. Obesity associated nutrient overload 
causes hypertrophic expansion of adipocytes, which become dysfunctional due to their limited capacity 
to store further lipids. Finally, the inability of adipocytes to store the excess calories results in the 
ectopic accumulation of lipids, and lipotoxicity, which is one of the contributing factors to the 
pathologies associated with MetS [21]. 
 
Adipose tissue is an active endocrine organ, secreting several hormones, and adipokines. Leptin was 
one of the first adipokines to be discovered [22]. Leptin regulates central energy metabolism, and 
promotes satiety by its action on the hypothalamic neurons. The expanding fat mass in obesity is 
associated with increased plasma leptin concentrations. However, the higher circulating levels of leptin 
fails to prevent the development of obesity in mouse models of obesity, and as well as in obese human 
subjects [23]. Ultimately, a combination of factors including reduced expression of leptin receptor in 
the hypothalamus, and an impaired leptin signaling, lead to leptin resistance [23].  
 
Adiponectin is one of the most abundantly secreted adipokines by the healthy adipose tissue [24]. 
However, plasma adiponectin levels drop significantly in obese individuals [25]. The injection of 
adiponectin in mouse models has been shown to improve insulin resistance [26], [27]. Therefore, 
obesity induced reduction in adiponectin levels promotes insulin resistance. 
 
The dysfunctional adipocytes have an impaired secretion of adipokines, and release more of the pro-
inflammatory cytokines like TNF and IL-6, and chemo-attractants like MCP-1 [28]. The pro-
inflammatory cytokines and chemo-attractants alter the local and systemic inflammatory milieu, and 
attract macrophages, and infiltrating immune cells, causing a state of chronic low grade inflammation 
in the adipose tissue. Adipose tissue inflammation is fundamental to the pathophysiology of obesity 
related metabolic dysfunction [29]. 
 
Obesity related adipocyte hypertrophy increases the size of adipocytes, resulting in diminished blood 
supply and restricted access to nutrients and oxygen, causing a hypoxic stress [30]. Studies indicate the 
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involvement of hypoxia in adipose tissue fibrosis, and inflammation [31], [30]. Moreover, hypoxia has 
been shown to cause polarization of the adipose tissue macrophages (ATMs) to the more inflammatory 
M1 state [32]. The paracrine and endocrine effects of adipokines can impact the metabolism of different 
organs and contribute further to the pathology of obesity and associated disorders. Therefore, it is 
necessary to understand the molecular mechanisms underlying the dysregulation of adipose tissue in 
obesity, and its effects on adipokine secretion in order to develop novel therapeutics for obesity. The 
figure below describes the key features of obesity mediated adipose tissue dysregulation. 
 
  
 
 
 
 
Fig. 3: Dysregulation of adipocytes in obesity. Obesity promotes the hypertrophic expansion of adipocytes, alters 
adipokine secretion, and augments the release of free fatty acids, and chemo-attractants. Plasma leptin 
concentration goes up, and adiponectin level decreases during obesity. The dysregulated adipocytes secrete more 
pro-inflammatory adipokines, which promotes Infiltration of macrophages and immune cells into the dysfunctional 
adipose tissue, and triggers a chronic inflammatory state characterized by the presence of pro-inflammatory M1 
macrophages. The increased amounts of free fatty acids, and inflammation, promote insulin resistance(Adapted 
from [28]). 
 
1.3 Pancreas 
1.3.1 Anatomy and functions 
 
The pancreas is an elongated, tapered organ located in the upper abdomen behind the stomach. It 
consists of three main parts namely, the head, the body, and the tail. The head of the pancreas is 
positioned on the right side of the organ, and lies in the loop of the duodenum. The body of the pancreas 
is tapered, and extends upwards, and the tail of the pancreas ends near the spleen.  
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The pancreas consists of the exocrine, and the endocrine glands. The pancreas has digestive and 
hormonal functions. The exocrine tissue constituting the majority of the pancreas, is composed of the 
acinar tissue, and secretes enzymes like trypsin and chymotrypsin, amylase, and lipase that help digest 
the ingested proteins, carbohydrates, and fats respectively. The enzymes are secreted in an inactive 
form by the pancreas, and are drained into the pancreatic duct, which joins the common bile duct. Upon 
entering the duodenum, they get activated.  
 
The endocrine pancreas consists of the islets of Langerhans, which is composed of several different 
types of cells. The -cells (produce glucagon), -cells (secrete insulin and amylin), -cells (secrete 
somatostatin), PP-cells (produce pancreatic polypeptide), and -cells (produce ghrelin). The main 
hormones secreted by the endocrine pancreas are insulin, glucagon, and somatostatin. Insulin is an 
anabolic hormone, and regulates the levels of glucose in the bloodstream, and promotes uptake of 
glucose by liver, muscle, adipose tissue, and other organs. Glucagon on the other hand has the opposite 
effect of insulin in glucose regulation, and promotes the release of stored energy into the bloodstream. 
Somatostatin reduces the rate of absorption of nutrients from the contents in the intestine. Finally, the 
pancreatic polypeptide is involved in the auto-regulation of the secretory activities of pancreas, and 
functions to reduce appetite. 
 
1.4 Pancreatic cancer 
1.4.1 Epidemiology 
 
The worldwide annual incidence rate for pancreatic cancer is approximately 8 out of 100,000 persons 
[33]. As of 2012, pancreatic cancer was the 10th most common cancer in men, and 6th most common 
cancer in women, in Germany (Fig. 4). Pancreatic cancer was the 4th most common cause of cancer 
related mortality in both men and women in 2012, in Germany (Fig. 5). Pancreatic cancer is one of the 
most aggressive malignancies, as its rate of incidence almost equals the mortality rate. Pancreatic cancer 
has one of the most dismal prognosis, with a 5-year survival rate of a mere 8% for both sexes, in Germany 
[34], (Zentrum für Krebsregisterdaten, Robert-Koch-Institut). Due to the absence of specific symptoms, 
the disease escapes diagnosis in its formative stages [35].  
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Fig. 4: Cancer incidence in Germany: Percentage of common tumor sites on all new cancer cases in Germany in 
2012 (Excluding non-melanotic skin cancer) - Zentrum für Krebsregisterdaten. Robert-Koch-Institut  
 
 
 
 
 
 
Fig. 5: Cancer mortality in Germany: Percentage of common tumor sites of all cancer deaths in Germany in 2012. - 
Zentrum für Krebsregisterdaten. Robert-Koch-Institut  
 
1.4.2 Common gene mutations in PDAC 
 
Studies have identified certain signature gene mutations in KRAS, CDKN2A, TP53, BRCA2, and 
SMAD4/DPC4 genes, which contribute to the biological characteristics and progression of pancreatic 
carcinoma (Table. 1) [35]. The majority of the tumors originate in the exocrine ductal tissue. It has been 
Incidence 
Mortality 
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observed that abnormal ductal structures called PanIN lesions (pancreatic intraepithelial neoplasia), 
often precede the occurrence of pancreatic ductal adenocarcinoma (PDAC) [35]. 
 
Tumor type Histological features Mutation 
Adenocarcinoma Ductal morphology KRAS, CDKN2A, TP53, SMAD4 
Acinar cell carcinoma Zymogen granules APC/-catenin 
Pancreatic endocrine tumors Hormone production MEN1 
Serous cystadenoma Ductal morphology, cystic growth VHL 
 
Table 1: Types of pancreatic cancer neoplasms. Different types of tumors can originate in the pancreas, determined 
by their histological similarity to different cell types. They show specific clinical and genetic profiles. Pancreatic ductal 
adenocarcinoma (PDAC), originating in the exocrine ductal cells, is the most common type of cancer in the pancreas, 
contributing to as much as 85% of pancreatic malignancies (Adapted from [35]). 
 
1.4.3 Risk factors for development of PDAC 
1.4.3.1 Hereditary, gene mutations, pancreatitis, and type 2 diabetes mellitus (T2DM) 
 
Having a family with at least 2 affected first degree relatives, poses an 18-fold higher risk for PDAC than 
random cases [36]. Germline mutations in genes like BRCA, p16, STK11/LKB1, and PRSS1, have been 
linked to the development of hereditary pancreatic cancer syndromes [36]. 
 
Hereditary pancreatitis significantly increases the risk for PDAC [37]. It is a rare disease, and is thought 
to arise due to a mutation in the trypsinogen gene, which might be affecting the activation of 
trypsinogen or preventing its autolysis, leading to pancreatic inflammation [37], [38]. Hereditary 
pancreatitis poses a 53-fold higher risk of developing pancreatic cancer, in comparison to unaffected 
individuals [38].  
 
Meta-analyses have shown that diabetics have a 2-fold higher risk for developing pancreatic cancer, 
compared to non-diabetics [13]. It is not clear if diabetes is a cause or consequence of pancreatic cancer. 
Diabetes could manifest due to impairment of pancreatic -cells, as a consequence of pancreatic cancer. 
However, in the presence of diabetes, the tumor cells could be exposed to high levels of insulin, and insulin 
is known to promote tumor growth. Therefore, hyperinsulinemia could be the link between T2DM and 
pancreatic cancer [39]. 
 
1.4.3.2 Age, sex, smoking, and alcohol consumption 
 
Pancreatic cancer is rare before the age of 55, and the median age of onset is 71 years [33]. Also, the 
incidence of pancreatic cancer is higher in men than in women [33]. Pancreatic cancer incidence rates 
are significantly greater in persons of an African origin, compared to any other racial origin 
(http://seercancergov/statfacts/html/pancreashtml). The reason for these racial differences are 
unknown [33]. 
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Smoking is one of the most well-known modifiable risk factor for PDAC, contributing upto 20-30% of 
PDAC cases [40]. Long-term smokers have a 2-fold higher probability of developing PDAC than non-
smokers [41]. Alcohol was identified as an independent risk factor for PDAC, however only in heavy 
alcohol consumers [40]. Smoking was found to be a strong confounding factor for alcohol-induced 
pancreatic cancer  [42]. 
 
1.4.4.3 Obesity and PDAC risk 
 
Overweight, and obesity not just increase the risk of CVD, and T2DM, but also of many different types 
of cancers [16]. In fact, studies have shown that obesity accounts for 20% of all cancers [43]. Cancers 
that are most frequently associated with a higher BMI are those of the endometrium, breast, kidney, liver, 
esophagus, and pancreas. The altered hormonal milieu in obesity influences these tumors selectively. 
Obesity causes significant pathological modifications in the morphology and functions of adipose tissue, 
involving alterations in pro-inflammatory adipokine secretion, lipolysis and free fatty acid generation, and 
immune cell infiltration. Together, these changes lead to insulin resistance, and a state of chronic 
inflammation, both of which are involved in carcinogenesis [16]. BMI > 30 is significantly associated with 
increased risk of pancreatic cancer [44].  
 
The metabolic dysregulation of visceral fat in obesity has been shown to cause fat accumulation or 
steatosis in the pancreas, which is a risk factor for pre-cancerous lesions (PanIN) that might progress to 
pancreatic cancer [45]. Autophagy is a process that under normal conditions, reduces inflammation. 
However, in mouse models, obesity and high-fat diet are known to inhibit autophagy, thereby 
augmenting inflammation [46]. Pancreatic cancer is known to be highly desmoplastic, characterized by 
activated stellate cells and build-up of the extra-cellular matrix (ECM) [47]. Desmoplasia promotes 
tumor cell migration, and metastasis, and most importantly prevents drug diffusion, causing chemo-
resistance. Obesity associated inflammation augments desmoplastic response in the pancreas, and 
contributes to drug-resistance [47]. Understanding the connection between inflammation, autophagy, 
and obesity could help identify new therapeutic targets, and develop effective treatments for PDAC 
[46]. 
 
Communication between dysfunctional adipocytes, and pancreas through secreted adipokines could be 
an important mechanism linking obesity and PDAC progression. Better understanding of the tumor 
promoting effects, and mechanism of action of such secreted factors on PDAC progression would pave 
the way for development of better therapeutics. 
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Fig. 6: Mechanisms linking obesity and PDAC. The interaction between HFD/obesity, inflammation, and oncogenic 
Kras signaling promotes PDAC progression. Studies in mouse models (LSL-Kras/Ela-CreERT mouse) showed that HFD 
feeding for 30 days increases Kras activity, upregulates COX-2 expression, activates Erk, causes significantly more 
PanIN lesions, and increases the severity of chronic pancreatitis compared to the mice on control diet. The same 
mice, when placed on a HFD for a prolonged period, proceed to develop PDAC from PanIN lesions. Inhibition of COX-
2 ameliorates the effects of HFD on pancreatic tumor progression [48]. On the contrary, caloric restriction impedes 
obesity, and reduces the growth of murine Panc02 allografts, and xenografts from human pancreatic cancer. Calorie 
restricted mice had lower IGF-1 levels, and the reduced pancreatic cancer growth was potentially mediated through 
reduced NFB activation associated with IGF-1 signaling (Adapted from  [49],  [50]). 
 
 
1.5 Transcriptional co-factor: Transducin beta like related (TBLR) 1 
 
1.5.1 Nuclear transcription factors and cofactors  
 
Eukaryotic transcription is a complex process involving an intricate, and concerted action of several 
macromolecules. Nuclear receptors (NR) are transcription factors that are activated by ligand binding, and 
function to activate (or repress) the transcription of specific downstream target genes [51]. Several 
receptors like the steroid receptors, estrogen receptor (ER), glucocorticoid receptor (GR), retinoic acid 
receptor (RAR), thyroid hormone receptor (TR), and receptors for fatty acids and prostaglandins, belong 
to the nuclear receptor class. Orphan receptors without any clearly identified ligands, are also a part of 
the NR superfamily [52]. Upon binding to its ligand, a series of events are triggered wherein the NR 
undergoes a conformational change, and can for e.g. induce receptor dimerization, import to the nucleus, 
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and bind to target DNA sequences [51]. The conformational change can also expose binding sites for 
transcription co-factors. 
 
Transcription cofactors interact with NRs, and other transcription factors to activate (coactivators) or 
repress (corepressors)  target gene expression [53]. They do so by modifying specific lysine residues on 
histones, which changes the local chromatin structure, making it more or less accessible to the 
transcription machinery. The coactivators most often have an intrinsic histone acetyltransferase (HAT) 
activity, and acetylate specific lysine residues of histone proteins, neutralizing its charge and promoting 
the unwinding of DNA from the associated histone to promote transcription. On the other hand, most 
corepressors recruit histone deacetylases (HDAC) to hydrolyze the acetyl residues and restore the positive 
charge to histones, strengthen the DNA-histone interaction, and inhibit basal transcription machinery. 
Both the coactivators, and corepressors, have distinct binding motifs. The NR coactivators are recruited 
in a ligand-dependent fashion (e.g.: CREB binding protein, p300 etc.). The NR corepressors on the other 
hand, specifically bind to ligand free receptor (e.g.: NCoR2/SMRT, RIP140 etc.). 
 
1.5.2 TBLR1 is part of a transcriptional corepressor complex 
 
TBLR1 (Transducin beta like related 1) is a transcriptional co-factor, and a component of the SMRT/NCoR1 
corepressor complex [54]. TBLR1 promotes repression of target gene expression, upon binding to ligand 
free nuclear receptors like TR (Thyroid hormone receptor) [55], [56]. The human gene encoding TBLR1 is 
located on chromosome 3, and contains 18 exons [54], [55]. TBLR1 has two more isoforms, namely TBL1X 
and TBL1Y, which are also encoded by the same gene [57].  
 
Previously, it has been demonstrated that TBLR1 plays a critical role in adipocyte lipid metabolism, and 
that mice lacking TBLR1 (Adipose Tissue specific KnockOut of Tblr1, ATKO) in their adipose tissue have 
an impaired lipolysis [58]. Upon exposure to a high fat diet, the ATKO mice were found to gain more 
weight, develop glucose intolerance, and become insulin resistant [58].  
 
Transcriptional dysregulation in the adipocyte, particularly those that lead to aberrant adipocyte energy 
metabolism, can serve as a link between obesity and adipose tissue dysfunction. Such changes in the 
adipose tissue can result in an altered adipokine secretion, potentially mediating pro-tumorigenic signals 
to tumors. Given that, ATKO mice have an impaired adipose tissue metabolism, they can serve as an 
experimental mouse model of metabolic dysfunction. The link between TBLR1 and PDAC is not known. 
Therefore, further research is required to understand the contribution of TBLR1 deficient adipose tissue 
to PDAC progression.  
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1.6 Adipokines and PDAC 
1.6.1 Dysregulated adipokines provide pro-tumorigenic signals 
 
Adipokines are secreted polypeptide cytokines, predominantly secreted by white adipocytes [59]. Obesity 
leads to alterations in the morphology, immune status, and vasculature of the adipose tissue, and causes 
changes in the secretory profile of adipose tissue [17]. The obese adipose tissue secretes more of the pro-
inflammatory adipokines like TNF, IL-6, leptin, and Plasminogen activator inhibitor 1 (PAI1), resistin etc. 
[17]. The altered adipokine secretion, and a pro-inflammatory state favor tumorigenesis [59]. Adipokines 
like IL-6, and leptin have been linked to activation of cancer stem cells, and increased tumor cell survival 
[59]. On the other hand, the serum levels of adiponectin, an anti-inflammatory adipokine associated with 
improving insulin sensitivity, , goes down in obesity [60], [61]. Serum adiponectin levels have been 
negatively correlated to CRC (Colorectal cancer) [62], [63]. The association between reduced adiponectin 
levels in obesity and PDAC are not clearly understood, however it is possible that increased insulin 
resistance, and inflammatory cytokines linked to lower adiponectin levels, could be an indirect mechanism 
[61]. Effect of adipokines on PDAC tumorigenesis is an ongoing field of research, and efforts in this 
direction would help gain a better understanding of the paracrine and endocrine effects of dysregulated 
adipose tissue on pancreatic cancer progression, and find safer and better treatment options for this 
deadly malignancy. 
 
1.7 Aim of the project 
 
Dysregulated adipose tissue metabolism is known to be associated with the progression of several 
cancers. The aim of this study was to investigate how obesity affects PDAC progression. We hypothesized 
that the adipose tissue, communicates with the tumor cells through secreted protein factors, which have 
a pro-tumorigenic effect on PDAC. This was to be achieved by comprehensive in vitro experiments 
exposing PDAC cells to the conditioned media from murine 3T3-L1 cells, or from primary mouse 
adipocytes. We aimed to investigate the in vitro effects of the conditioned media on tumor cell viability, 
proliferation, migration, and invasion and to validate these effects in vivo using different mouse models 
of obesity. Subcutaneous Panc02 tumor implantations were performed to study the effects of obesity on 
PDAC progression in vivo. The ultimate goal was to identify differentially regulated candidate genes 
between lean and obese white adipose tissue, that encoded secreted proteins. With these studies, we 
aimed to identify potential crosstalk between dysfunctional adipose tissue and PDAC. 
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2 RESULTS 
 
2.1 3T3-L1 adipocyte conditioned media has pro-tumorigenic effects on PDAC 
cell lines in vitro  
2.1.1 3T3-L1 ACM increases the viability and proliferation of Panc02 cells in vitro 
 
To investigate the effect of adipocyte-conditioned media (ACM) on PDAC progression in vitro, 3T3-L1 cells 
were used as an in vitro model of mouse adipocytes. Panc02 cells were either treated with the supernatant 
from differentiated adipocytes, or undifferentiated fibroblasts, generated from 3T3-L1 cells. The effects 
on tumor cell proliferation, and viability were measured by EdU assay, and CCK-8 assay, respectively.  
 
 
 
 
 
Fig. 7: Viability and proliferation time course assay of Panc02 with 3T3-L1 ACM and FCM. a) CCK-8 Viability assay 
b) EdU Proliferation assay. n=4,  
 
 
Compared to the fibroblast-conditioned media (FCM), the adipocyte conditioned media (ACM) 
significantly increased the viability of Panc02 cells, with increasing treatment time (Fig. 7 a). The ACM also 
increased the proliferation of Panc02 cells all time-points, and the proliferation effects did not increase 
further after 72 hrs. of treatment with ACM. The serum-free media (SFM) was used as a negative control. 
We were further interested to investigate the effects of ACM on other tumor characteristics like 
migration. 
 
2.1.2 Adipocyte conditioned media from 3T3-L1 cells increases the migration of PDAC cell lines 
in vitro 
 
To determine if the ACM affected the migration of PDAC cells, we performed trans-well migration 
assays. Here, the tumor cells were plated on the upper compartment of a cell permeable membrane, 
and the conditioned medium (ACM/FCM) from 3T3-L1 cells was placed on the bottom compartment as 
the chemo-attractant. DMEM with 10% FBS was used as a positive control, and serum-free media (SFM) 
was used as a negative control. After an incubation period of 16-18 hrs. in the cell culture incubator at 
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37°C and 5% CO2, the cells that migrated to the bottom side of the permeable membrane were stained 
with crystal violet, and quantified manually or using the ImageJ software.  
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Fig.  8:  Trans-well migration of Panc02, Panc8680, Capan1 and BxPC3 with 3T3-L1 conditioned media. PDAC cell lines were 
plated on trans-well permeable membranes, and ACM or FCM from 3T3-L1 cells were added on the lower compartments. 10% FBS 
containing DMEM, and SFM were used as positive and negative controls, respectively. The cells were allowed to migrate for 16-
18 hrs. in the cell culture incubator. The cells that migrated to the bottom surface of the membrane were stained and quantified 
manually for-  a) Panc02, b) Panc8680, c) Capan1, and using ImageJ software for d) BxPC3 cells. Microscope image for migration 
of a) Panc02 f) Capan1 g) BxPC3 with intact and heat-denatured conditioned media. n=4, means ±SEM, *indicates 
significance. 
 
The ACM significantly increased the migration of the murine cells: Panc02, and Panc8680 (Fig. 8 a, b, e), 
and the human cell line Capan1 (Fig. 8 c, f). Compared to the negative control-SFM, only the ACM from 
the 3T3-L1 cells induced migration, and not the FCM.  
 
For the human PDAC cell - BxPC3, we additionally heat-inactivated the conditioned media. This was 
performed to evaluate if there were any changes in the migration promoting effects of the 3T3-L1 - 
ACM upon heat-denaturation. The BxPC3 cells migrate as tightly packed colonies, and are difficult to 
quantify manually. Therefore, ImageJ software was used to quantify the area of migrating cells. 
Surprisingly, only the intact, non- heat denatured ACM promoted the migration of BxPC3 cells. 
However, the heat-inactivated ACM lost its migration promoting effects (Fig. 8 d, g).  
 
Next, we wanted to investigate the effects of 3T3-L1 conditioned media on PDAC tumor invasion in 
vitro. For this we decided to utilize matrigel-coated trans-well membranes as an in vitro system. 
 
2.1.3 3T3-L1 adipocyte conditioned media significantly increases the invasion of Panc02 cells 
 
Tumor cell metastasis is a key process for the development of secondary tumors at distant organs. The 
metastatic cascade is complex, and involves several coordinated and sequential processes. Some of the 
early steps involved in tumor cell metastasis are: the loss of cell-cell contact to be able to dissociate 
from the primary tumor site, followed by invasion of the stroma by the secretion of factors/enzymes 
that help to degrade the basement membrane and the extra-cellular matrix (ECM) components, and 
the modulation of proteins involved in tumor cell motility/migration.  
 
We hypothesized that adipocyte secreted factors could potentially alter the tumor cell invasiveness. 
This prompted us to investigate if the ACM from 3T3-L1 cells affected the invasiveness of PDAC cell 
lines. We performed trans-well invasion assays by plating Panc02 cells on the top part of a matrigel- 
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coated trans-well permeable membrane, and placed ACM/FCM from 3T3-L1 cells in the bottom 
compartment, as the chemoattractant. DMEM supplemented with 10% FBS, and SFM were used as 
positive and negative controls, respectively. Following an incubation time of 24 hrs., the invading cells 
on the bottom part of the invasion chambers were stained with crystal violet, and counted manually 
under the microscope. 
 
 
 
 
 
 
 
 
Fig.  9:  Trans-well invasion of Panc02 with 3T3-L1 conditioned media. Panc02 cells were plated overnight on 
matrigel-coated trans-well invasion inserts, with ACM or FCM from 3T3-L1 cells as the chemo-attractant in the 
bottom chamber. The invading cells were stained with crystal violet and counted manually after 24 hrs. a) 
Quantification of invading Panc02 cells b) Microscopic images of invading Panc02 cells. 
 
 
The ACM from 3T3-L1 cells significantly increased the invasiveness of Panc02 cells through the matrigel 
coated membrane, compared to the conditioned media from undifferentiated 3T3-L1 fibroblasts, or the 
SFM (Fig. 9 a, b).  
 
Based on the above results, we hypothesized that secreted factors from adipocytes have tumor promoting 
effects on PDAC cell lines in vitro. Going forward, we aimed to validate our hypothesis using different in 
vivo mouse models. Above all, we wanted to identify the secreted factors from white adipocytes that 
could potentially mediate these effects on PDAC cells. Therefore, we decided to employ ATKO (Adipocyte 
specific Knockout of Tblr1) mice, as well as ob/ob and db/db mice, as in vivo mouse models of obesity.  
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2.2 Analysis of subcutaneous Panc02 tumors implanted into wt and ATKO mice 
 
2.2.1 ATKO mice have significantly higher body weight and fat mass compared to wt control 
mice 
 
We used ATKO mice as an experimental model of MetS. It has been shown before that the ATKO mice 
have an impaired lipolysis, have hypertrophic adipocytes, and gain more weight upon high-fat feeding 
[58]. In order to investigate, if the absence of Tblr1 in the adipose tissue accelerates PDAC progression in 
vivo, we implanted Panc02 cells subcutaneously into the flanks of 12 weeks old- wt and ATKO mice.  
 
Tumor progression was monitored non-invasively by measuring luminescence signal from the SC tumors, 
using the in vivo imaging system (IVIS). We measured the body weight, blood glucose, fat mass, and lean 
mass of the mice during the entire course of the experiment. The fat mass, and lean mass were 
determined by placing the mice inside the ECHO MRI system. Finally, the tumor, the abdominal WAT, and 
the inguinal WAT, were harvested after sacrificing the mice. 
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Fig. 10: Body weight, blood glucose, and body composition measurements by ECHO MRI, for wt and ATKO mice. 
A) Body weight, b) Blood glucose c) Fat mass, and d) Lean mass, of wt and ATKO mice were measured using weighing 
scales and ECHO MRI system. n=10, means ±SEM, *indicates significance.  
 
The ATKO male, and female mice had significantly higher body weights than the wt control mice (Fig. 10 
a). There was no significant difference in the blood glucose levels of wt and ATKO male mice, but the ATKO 
female mice had significantly higher serum glucose levels, than wt mice (Fig. 13 c). In line with the higher 
body weight, the fat mass was significantly higher, and the lean mass was significantly lower in the ATKO 
mice, compared to the wt littermates (Fig. 10 c, d). 
 
Next, we performed IVIS measurements to evaluate if the increased body weight and fat mass of the ATKO 
mice could contribute to greater tumor growth. 
 
2.2.2 Subcutaneous Panc02 tumors grew significantly larger in the ATKO mice 
 
To monitor the tumor progression non-invasively, we measured luminescence output from the luciferase-
expressing Panc02 tumors, using the IVIS system. The ATKO and wt mice were intra-peritoneally injected 
with a luciferin solution, at a dosage of 150 g/g of body weight, and anesthetized with vaporized 
isoflurane before placing them inside the IVIS imaging system. Pairs of wt and ATKO mice were imaged 
simultaneously for a better comparison. 
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Fig. 11: IVIS measurement of tumor luminescence from male and female wt and ko mice bearing SC Panc02 
tumors: Mice were injected with luciferin (150 g/g of body weight, 10 l/g body weight), and anesthetized with 
vaporized isoflurane before measuring the luminescence signal. Quantification of IVIS luminescence signals for 
tumors from (a) male wt and ko mice, (b) female wt and ko mice, IVIS images for tumors from (a) male wt and ko 
mice (d) female wt and ko mice. n=10, means ±SEM, *indicates significance.    
 
The luminescence signal was significantly higher from the tumors of ATKO male and female mice. As the 
luminescence measurement is directly proportional to the tumor size, we concluded that the 
subcutaneous Panc02 tumors were significantly larger in the ATKO mice (Fig. 11 a, b). Furthermore, we 
wanted to quantify the tumor mass, and the abdominal-, and inguinal- fat mass from wt and ATKO mice. 
 
2.2.3 Tumors, abdominal WAT, and inguinal WAT from ATKO mice weighed significantly more 
compared to wt mice 
 
In order to quantify the tumor mass, abdominal (ABD) fat mass, and inguinal (ING) fat mass, we weighed 
the respective tissue explants after sacrificing the mice. The ABD, and ING fat mass from the ATKO mice 
weighed significantly more in comparison to wt controls (Fig. 12 a, b). In line with the higher luminescence 
signal from tumors in the ATKO mice, the tumor mass was significantly greater in the ATKO mice, as 
compared to wt littermates (Fig. 12 c). 
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Fig. 12: Tumor, ABD, and ING fat mass from wt and ATKO mice: Mice were sacrificed after three weeks of tumor 
implantation and their a) ABD fat mass b) ING fat mass c) tumor weight and d) TG from tumor were measured on a 
weighing scale. 
 
We speculated if the higher tumor mass in the ATKO mice could be attributed to a higher fat content 
within the tumors. Therefore, we decided to quantify the triglyceride contents in the tumors from the 
wt and ATKO mice. 
 
2.2.4 Triglyceride levels in the tumors of wt and ATKO mice were similar 
 
In order to find out if the triglyceride (TG) content in the tumors contributed to the increased tumor 
mass in the ATKO mice, we extracted the TGs from the tumors and quantified them. Surprisingly, the 
TG content was lower in male ATKO mice compared to controls, while there was no significant 
difference between the females (Fig. 13 a, b). 
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Fig. 13: TG measurement from SC tumors. Quantification of tumor TG content from male (a), and female (b) wt  
and  AT KO m ice .  n =10,  means ±SEM, *indicates significance.  
 
As the TGs from the tumors were not consistently higher in the tumors from both male and female ATKO 
mice, we rationalized that TG could not be a reason for the higher tumor mass in the ATKO mice. 
Therefore, we performed histological analysis to investigate the cause of the greater tumor size in the 
ATKO mice. We reasoned that the tumors could be larger in the ATKO mice due to an increased adipocyte 
infiltration, or increased proliferation. To this end, we decided to perform H and E-, and Ki67- staining on 
the tumor paraffin sections.   
 
2.2.5 H and E- staining of subcutaneous Panc02 tumors from wt and ATKO mice did not show 
significant differences  
 
In order to investigate if adipocyte infiltration into tumors could be a contributing factor for the 
greater tumor mass observed in ATKO mice, we performed H and E- staining on the tumor paraffin 
sections. We did not observe any striking differences between the tumors from the wt and ATKO mice 
upon H and E- staining (Fig. 14). Also, we did not observe any particularly striking differences in the 
tumor adipocyte content between the treatment groups, by visually analyzing the H and E- stained 
sections under the microscope (Fig. 14). 
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Fig. 14: H and E- staining of Panc02 SC tumor sections from wt and ATKO mice.  (a) Male wt and ATKO mice, (b) 
female  wt  and  A TK O m i ce .  
 
We further wanted to investigate if the greater tumor size in the ATKO mice could be due to adipocyte 
infiltration into the tumors implanted in the ATKO mice. 
 
2.2.6 Ki67 staining from wt and ATKO mice did not show any striking differences in tumor cell 
proliferation 
 
To investigate if there were differences in proliferation between wt and ATKO tumors, we performed Ki67 
staining on tumor paraffin sections. The Ki-67 protein is localized in the nucleus of a cell during the G1, G2, 
S, and M phase of the cell cycle [64]. It is not present in the cells at Go phase, or in the resting cells [64]. 
Therefore, Ki-67 protein is routinely used as a proliferation marker, and anti-Ki67 antibodies are used to 
detect Ki-67 expression immuno-histochemically, in the paraffin embedded tissue sections.  
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Fig. 15: Ki67 staining of SC Panc02 tumors from wt and ATKO mice. (a) wt and ATKO males (b) wt and ATKO 
females 
 
 
 
As can be observed from the staining depicted in Fig. 15, there was no significant difference in the Ki-67 
staining between SC Panc02 tumors grown in wt and ATKO mice. Therefore, we could not detect any 
difference in the tumor proliferation between SC Panc02 tumors in wt and ATKO tumors. 
 
Going forward, we wanted to identify target genes that could be differentially regulated between tumors 
from wt and ATKO mice, which could explain the higher tumor mass in the ATKO mice. 
 
2.2.7 Gene expression analysis from tumors grown in wt and ATKO mice did not reveal any 
significantly differentially regulated candidate genes  
 
 
We performed microarray analysis to identify potential candidate genes, that could be differentially 
regulated between SC Panc02 tumors grown in the wt and ATKO mice. By doing so, we wanted to 
determine potential underlying genes, and pathways contributing to larger tumor growth in the ATKO 
mice that we observed. Three samples were tested per treatment group. 
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Fig. 16: Heat map for Microarray samples from wt and ATKO SC Panc02 tumors . n=3 per condition. 
 
 
Unfortunately, samples from the same treatment group did not cluster together due to high standard 
deviations (Fig. 16). Based on a p-value cut off of < or = 0.05 for significance, the microarray analysis could 
not identify any differentially regulated genes between wt and ATKO tumors. 
 
We decided to focus on in vitro trans-well assays, using conditioned media from wt or Tblr1 kd adipocytes, 
to establish a link between PDAC and Tblr1.  
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2.3 Trans-well assay of Panc02 with wt or Tblr1 knockdown ACM  
 
2.3.1 Adenovirus mediated knockdown of Tblr1 in 3T3-L1 adipocytes   
 
To investigate the effect of ACM from Tblr1 kd adipocytes on Panc02, 3T3-L1 adipocytes were infected 
with adenovirus encoding an shRNA Tblr1. The cells were differentiated until 10 days, followed by serum 
starvation for 4 hours, and the conditioned media was harvested. The knockdown was confirmed both at 
the mRNA, and the protein levels by qPCR and western blot analysis, respectively (Fig. 17). 
 
 
 
 
 
 
Fig. 17: Adenovirus mediated knockdown of Tblr1 in 3T3-L1 adipocytes. a) TBLR1 protein expression quantification 
b) Relative mRNA expression of Tblr1 measured by qPCR, and c) Western blot image showing TBLR1 kd. n=3, means 
±SEM, *indicates significance. 
 
We generated conditioned media from control and Tblr1 kd adipocytes, to utilize them as a chemo-
attractant in trans-well assay with Panc02. 
 
2.3.2 Viability and proliferation of Panc02 was not significantly affected upon treatment with 
Tblr1 kd conditioned media from 3T3-L1 adipocytes 
 
To investigate if the ACM from Tblr1 kd - 3T3-L1 cells had an impact on Panc02 cell viability and 
proliferation, we performed CCK-8 assay, and EdU assay, respectively. We treated Panc02 cells with the 
respective conditioned media for different time-points.  
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Fig. 18: Treatment of Panc02 cells with 3T3-L1- nc or Tblr1 kd ACM a) Viability by CCK-8 assay b) Proliferation 
by EdU Assay. n=4, means ±SEM. 
 
There were no significant differences in viability, as well as proliferation of Panc02 cells at any given time-
point of treatment with the control or the Tblr1 kd conditioned media from 3T3-L1 adipocytes (Fig. 18). 
 
We previously demonstrated that ACM from differentiated 3T3-L1 cells had a strong impact on PDAC cell 
proliferation, viability, migration, and invasion in vitro, which could be mediated by factors secreted from 
adipocytes. Hence, we decided to perform gene expression analysis from the WAT of a distinct congenital 
model of obesity, to identify differentially regulated genes between lean and obese adipose tissue 
mediating these effects. 
 
2.3.3 Microarray analysis from the inguinal WAT of wt and db/db mice reveals significantly 
regulated genes, including such which encode secreted proteins  
 
Microarray gene expression analysis was performed from the subcutaneous inguinal WAT of wt and db/db 
tumor bearing mice. The db/db mice lack the receptor for leptin (Lepr), and are a well-accepted 
monogenic mouse model of obesity. We observed that the subcutaneous Panc02 tumors grew 
significantly larger in the db/db mice, and therefore we hypothesized that secreted factors from the WAT 
of the db/db mice could potentially play a pro-tumorigenic role.  
 
With this analysis, we aimed to identify candidate genes that were differentially regulated in WAT of wt 
and db/db mice and hence could serve as a link between obesity and PDAC.  
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Fig. 19: Microarray from the WAT of wt and db/db, SC Panc02 tumor bearing mice: A) Heat map distribution 
for Microarray samples b) One Way ANOVA distribution. 
 
 
Although a total of 195 genes were significantly differentially regulated between the iWAT of wt and 
db/db mice, we were particularly interested to identify such candidate genes which encoded for 
secreted proteins. Based on the above criteria, five candidate genes were identified to be significantly 
differentially regulated: 
 
1. Lep (leptin)     Significantly upregulated in db/db iWAT 
2. Lcn2 (Lipocalin 2)    Significantly upregulated in db/db iWAT 
3. Lbp (Lipo-polysaccharide binding protein)  Significantly upregulated in db/db iWAT 
4. Saa3 (Serum amyloid a 3)   Significantly upregulated in db/db iWAT 
5. Angpt1 (Angiopoietin 1)   Significantly downregulated in db/db iWAT 
 
We aimed to determine if the above candidates were mediating their effects from the WAT on PDAC cells. 
For evaluating this, we decided to perform in vitro assays of PDAC cells following treatment with 
respective candidate in the form of conditioned medium. In order to generate such conditioned media, 
these candidates were to be overexpressed (OE) using plasmid OE constructs in human HEK293A cells, 
and knocked-down using siRNAs in murine 3T3-L1 cells. 
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2.3.4 Overexpression of candidate genes in HEK293A cells 
 
HEK293A cells were transfected with plasmid constructs to overexpress the candidate genes. We 
confirmed the overexpression of the candidate genes by qPCR (Fig. 20). Conditioned media enriched 
with secreted candidates was generated, by serum starving the HEK293A cells transfected with OE 
plasmid constructs, for 4 hours. HEK293A cells transfected with Gfp plasmid construct was used to 
generate control conditioned media.  
 
 
 
 
 
 
Fig. 20: qPCR data depicting the overexpression of candidate genes in HEK293A cells. 
 
Next, we performed viability and migration assays of PDAC cells with candidate OE-conditioned media 
from HEK293A cells. With such read-outs we aimed to investigate the potential effects of the candidates 
on PDAC tumorigenesis in vitro. 
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2.3.5 Migration of Panc02 with candidate overexpression-conditioned media 
 
In order to identify if any of the overexpressed candidates affected the migration of Panc02 cells, we 
serum starved the HEK293A cells that were transfected with OE constructs for Lep, Lcn2, Lbp, Saa3, and 
Angpt1 for 4 hours and collected the CM. The CM was used as a chemo-attractant for the trans-well 
migration assay and Panc02 cells were plated on the top part of the trans-well permeable membranes, 
and allowed to migrate for 16-18 hrs. in the cell culture incubator. 
 
 
 
 
 
Fig. 21: Trans-well migration of Panc02 with candidate overexpression-conditioned media from HEK293A 
cells. 
 
There was no significant effect of any of the candidate OE-CM on Panc02 migration. The control 
supernatant with Gfp overexpression induced the migration of Panc02 cells as well (Fig. 21). Also, we did 
not see any effect of the candidate OE-CM on Panc02 proliferation, and viability (data not shown).  
 
As we did not see any effect of candidate OE-CM on PDAC cell proliferation, and viability, we decided to 
use alternate approach and perform transient knockdown of candidate genes in mature 3T3-L1 adipocytes 
using siRNA. The knockdown-CM was to be generated from the siRNA transfected 3T3-L1 cells, to be used 
later for assays with Panc02 cells. 
 
2.3.6 Knockdown of microarray candidates in mature 3T3-L1 adipocytes 
 
We performed transient knockdown of candidate genes in 3T3-L1 adipocytes by transfecting them with 
multiple siRNAs on day 9 of differentiation. We then changed media on day 10, serum starved the 
adipocytes on day 12 for 4 hrs., and collected the respective knockdown conditioned media on day 12. 
We performed qPCR analysis to identify the siRNA construct that gave the best knockdown (Fig. 22).  
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Fig. 22: qPCR data showing the knockdown of candidate genes in mature 3T3-L1 adipocytes. 3T3-L1 cells 
were transfected on day 9 of differentiation with siRNAs against candidate genes, and the media was changed on 
day 10, and knockdown condition media was collected 48 hours later on day 12, after serum staving cells for 4 hrs. 
 
There was no significant effect of any of the knockdown-CM on Panc02 migration, proliferation, and 
viability (data not shown).  
 
As we did not see any effect of OE as well as kd conditioned media treatments, we decided to use 
recombinant candidate proteins instead to evaluate their effects on PDAC cell line viability, proliferation, 
and migration. 
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2.3.7 Viability, and migration of PDAC cells with recombinant candidate proteins 
 
We treated PDAC cell lines with different concentrations of recombinant candidate proteins, and 
performed viability, and migration assays. None of the candidate proteins had any effect on the 
proliferation, and migration of cell lines that we tested (data not shown). However, we found that 
recombinant leptin (LEP) increased the viability of Panc02 and BxPC3, compared to serum free media 
(SFM) (Fig. 23). 
 
 
 
 
 
Fig. 23: Viability of Panc02 and BxPC3 with recombinant candidate proteins.  a) Panc02, and b) BxPC3. 
 
Leptin was the primary candidate that affected the viability of PDAC cell lines tested above. As PDAC forms 
a solid tumor mass in vivo, we wanted to investigate the effect of recombinant candidates on 3-
dimensional spheroid invasion in vitro. 
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2.4 Recombinant leptin increases the invasiveness of tumor 3D spheroids, and 
chemo-resistance of PDAC cell lines to gemcitabine  
 
2.4.1 Leptin increases the invasiveness of BxPC3 spheroids through collagen I matrix 
 
Traditionally, anti-cancer drugs were screened for their in vitro potency against tumor cells, cultivated 
as 2-dimensional (2D) cultures in cytotoxicity assays [65]. However, several of them with great efficacy 
against tumor cells in the 2D monolayer cultures in vitro, have failed in clinical trials [66], [67]. Although, 
2D monolayer cultures are an invaluable research tool, they do not reflect the complexity, and 
heterogeneity of an in vivo tumor [65]. Tumors grow as a closely packed 3-dimensional (3D) mass in 
vivo. Therefore, 3D spheroid cultures of tumor cell lines are a better representative of the in vivo tumors 
[65]. 
 
In order to investigate the effect of recombinant LEP on 3D spheroid cultures of PDAC cells, we 
generated spheroids of BxPC3, and Panc8680 by the hanging drop method. The spheroids were carefully 
placed within collagen I matrix in 96 well plates. Throughout the procedure, recombinant LEP was 
present in the cell culture media/collagen matrix at specific concentrations as indicated below. The 
spheroids were imaged at different time-points with a microscope to measure the area of the spheroid 
invasion. 
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Fig. 24. Effect of recombinant LEP on BxPC3, and Panc8680 spheroid invasion through collagen I matrix. 
BxPC3, and Panc8680 spheroids were generated by hanging drop method, and transferred into collagen I matrix. 
Different concentrations of LEP was added, and the spheroid area was calculated from microscopic images at 
different time points. Quantification of the area of spheroid invasion of a) BxPC3 and b) Panc8680. c) Microscopic 
images of BxPC3 spheroids in collagen I matrix after treatment with different concentrations of LEP. 
 
 
Recombinant LEP at a concentration of 10 nM, significantly increased the invasion of BxPC3, and 
Panc8680 spheroids through collagen I matrix (Fig. 24). We therefore, decided to focus on the role of 
LEP based on its effects on viability, and invasion of PDAC cell lines. 
 
Gemcitabine is the primary chemotherapeutic for treating pancreatic cancer. It is a nucleoside analog, 
with a H-atom being replaced by a F-atom at the 2’ carbon of deoxycytidine. As chemo-resistance to 
gemcitabine is a major issue in the treatment for PDAC that affects the disease prognosis, we wanted 
to evaluate if leptin affected the chemo-resistance of PDAC cell lines to gemcitabine. 
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2.4.2 Recombinant leptin significantly increases the viability and chemo-resistance of PDAC 
cell lines in vitro 
 
Chemo-resistance is a huge problem in pancreatic cancer. Gemcitabine is the standard chemotherapy 
administered to treat PDAC. We therefore, wanted to investigate if recombinant leptin treatment affected 
PDAC sensitivity to gemcitabine in vitro. Tumor cell viability and proliferation were measured after 
treating PDAC cell lines with LEP and gemcitabine. 
 
 
 
 
Fig. 25: Viability and chemo-resistance of PDAC cell lines after recombinant leptin treatment, measured by 
CCK-8 assay. PDAC cell lines were plated on 96-well plates on day1, and allowed to attach overnight. LEP was 
added on the following day2, and 1 M gemcitabine was added on day 3. The viability measurement was 
performed with CCK-8 reagent for a) Panc02 b) BxPC3 c) Panc8680. 
 
 
Recombinant LEP treatment significantly increased the viability and chemo-resistance of the PDAC cell 
lines: Panc02, Panc8680, and BxPC3 after treatment with gemcitabine (Fig. 25). 
 
We found that recombinant LEP strongly affected the in vitro viability-, spheroid invasion-, and chemo-
resistance to gemcitabine-, of distinct PDAC cell lines. Going forward, we wanted to investigate the 
progression of subcutaneous Panc02 tumors in mouse models of obesity with an impaired leptin 
signaling. 
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2.5 PDAC progression in congenital mouse models of obesity: ob/ob and db/db 
mice 
2.5.1 Experiment plan for study of Panc02 tumor progression and chemo-sensitivity to 
gemcitabine in distinct monogenic mouse models of obesity: db/db and ob/ob mice 
 
We performed subcutaneous Panc02 tumor implantations in wt, db/db, and ob/ob mice to investigate if 
the tumors progressed at different rates in these mice, and responded differently to gemcitabine 
treatment, depending on the in vivo leptin signaling. The db/db mice harbor a glycine to threonine 
mutation in the Lepr gene, which leads to a non-functional form of the long form of Lepr: Ob-Rb [68]. The 
mice homozygous for the mutation become markedly obese by three to four weeks after birth, have 
hyperinsulinemia by two weeks of age, and display polyphagia, polydipsia, polyuria, and have excess 
circulating leptin due to impaired leptin signaling at the cellular level. The ob/ob mice on the other hand, 
have a non-sense mutation in the ob gene encoding leptin. This mutation converts an arginine residue to 
a stop codon, leading to a non-functional and truncated protein [68]. Homozygous mutant ob mice gain 
significant weight compared to the control mice, and exhibit polyphagia, hyperinsulinemia, 
hyperglycemia, and suffer from reduced fertility. Both db/db, and ob/ob mice are well characterized 
congenic mouse models of obesity.  
 
The experiment was performed as shown in the schematic below (Fig. 28). We subcutaneously injected 
100,000 Panc02 cells per mouse, into the right flanks of all mice (20 mice/genotype). Once the tumors 
became palpable, half of the mice per genotype were treated with gemcitabine at 20mg/kg dose, on 
alternate days. The other half were treated with the vehicle, i.e. PBS.  The tumor volumes were measured 
thrice a week. The experiment was terminated as soon as the tumors in the PBS group reached the barely 
acceptable limit (humane end point; 1.5 cm on any single dimension). 
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Fig. 26: Experimental plan for study of SC Panc02 tumor progression and chemo-sensitivity to gemcitabine in 
wt, ob/ob and db/db mice. Mice were acclimatized for a week in the housing facility, and then implanted with 
Panc02 cells (100,000 cells/ mouse). Once the tumors were palpable, they were treated with gemcitabine 
(20mg/kg), or vehicle (PBS), on alternate days. Body weight, and tumor volumes were measured on alternate days. 
The mice were sacrificed when the PBS group developed tumors that reached the limit of 1.5 cm length on any 
dimension. 
 
2.5.2 Tendency for slower tumor growth, and better response to gemcitabine treatment 
observed in ob/ob mice compared to db/db mice  
 
To evaluate the impact of in vivo leptin signaling on pancreatic cancer progression, we performed 
subcutaneous Panc02 tumor implantations in wt, db/db, and ob/ob mice. The experiment was performed 
as explained in Fig. 26 above. 
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Fig. 27: Progression of SC Panc02 tumors in wt, ob/ob, and db/db mice. n=10 per group, means ±SEM. *, # indicates 
significance. 
 
 
The subcutaneous tumors grew significantly larger in the PBS group for all three genotypes (Fig 27 a, b, 
d). The tumor growth curves for wt, db/db, and ob/ob mice with and without gemcitabine treatment, are 
represented multiple times to clearly compare different treatment groups and genotypes (Fig. 27). The 
db/db-, and ob/ob- PBS group developed significantly larger tumors than the wt controls (Fig. 27 c, e). 
There was no significant difference between wt and db/db mice treated with gemcitabine, or wt and 
ob/ob mice treated with gemcitabine (Fig. 27 c, e). However, towards the end, there was a tendency for 
the ob/ob tumors to respond better to gemcitabine, compared to the db/db mice on gemcitabine, and 
the tumor volumes were significantly smaller in ob/ob gemcitabine group than the db/db on gemcitabine 
(Fig. 27 f). However, the experiment was terminated after four weeks of tumor implantation, as the PBS 
group in all genotypes developed tumors beyond the acceptable limit.  
 
As we previously observed that recombinant LEP increased the viability-, spheroid invasion-, and chemo-
resistance to gemcitabine-, of multiple PDAC cell lines, we wanted to generate stable Lepr knockdown 
cells, and determine their growth characteristics and response to gemcitabine in vitro, in comparison 
to wt cells. 
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2.5.3 Knockdown of Lepr in the murine PDAC cell line: Panc02  
 
Panc02 cells with a stable Lepr kd were generated using lentivirus mediated shRNA expression. The cell 
lines were generated by clonal selection. qPCR assay was performed to select the clones with lowest 
expression of the Lepr. The clones were selected, expanded, and stored in liquid nitrogen for future 
experiments. 
 
 
 
 
 
Fig. 28: Lentivirus mediated knockdown of Lepr in mouse PDAC cell line Panc02.  Five different shRNA 
constructs were used to generate stable Lepr kd cell lines. The knockdown cell lines were generated from single clone. 
n=4, means ± SEM, *indicates significance. 
 
 
As shown in the figure above, we could get best knockdown with the lentivirus construct 1 and 3 (Fig. 
28). We performed in vitro assays with these cell lines. However, we observed that the kd status was 
lost in stable cells with the due course of time, and with increasing passage numbers.  
 
In order to circumvent this issue, we decided to generate pooled knockdown cells with the same 
lentiviral shRNA constructs, and freeze several aliquots, and use shortly for in vitro experiments. The 
cells were to be used only for few passages, and fresh vials were thawed after 2-3 passages. The 
construct L2 gave the best knockdown, and hence we generated pooled cells with Lepr kd using shRNA 
construct 2, and used these cells for future experiments (Fig. 29). 
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Fig. 29: Lentivirus mediated knockdown of Lepr in mouse PDAC cell line Panc02.  Five different shRNA 
constructs were used to generate stable Lepr kd cell lines. The knockdown cell lines were generated from pool of cells 
infected with a specific shRNA construct. n=4, means ± SEM, *indicates significance. 
 
We wanted to compare the proliferation and viability of control and Lepr kd Panc02 cells. 
 
2.5.4 Viability and proliferation of wt (nc) and Lepr kd Panc02 cells in vitro  
 
In order to investigate the effects of Lepr knockdown on Panc02 viability and proliferation, we treated the 
wt and Lepr knockdown cells with gemcitabine, and performed the respective assays. 
 
 
RESULTS 40 | P a g e  
 
 
 
 
 
Fig. 30: Proliferation and viability of wt and Lepr kd Panc02 cells. wt and Lepr kd Panc02 cells were treated with 
gemcitabine a) Proliferation measured by BrDU assay b) Viability measured by CCK-8. 
 
To our surprise, the kd of Lepr in Panc02 cells increased the proliferation, and viability of Panc02 cells 
upon treatment with 3T3-L1 – ACM, and gemcitabine (Fig. 30 a, b). We also wanted to generate another 
human PDAC cell line with a stable Lepr kd and perform the above experiments. 
 
2.5.5 Knockdown of Lepr in human PDAC cell line AsPC1 
 
We generated AsPC1 cells with a stable Lepr kd to evaluate the effects of the kd on cell proliferation, and 
chemo-resistance upon gemcitabine treatment (Fig. 31).  We used lentivirus with human shRNA 
constructs for the knockdown. 
 
 
 
Fig. 31: Lentivirus mediated knockdown of Lepr in human PDAC cell line AsPC1. Five different shRNA constructs 
were used to generate stable Lepr kd cell lines. n=4, means ± SEM, *indicates significance. Experiment performed 
along with Eveline Molocea. 
 
We wanted to compare the proliferation and viability of control and Lepr kd human PDAC cell line: AsPC1. 
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2.5.6 Viability and proliferation of control and Lepr knockdown AsPC1 cells in vitro  
 
Next, we performed proliferation and viability assays with wt and Lepr kd AsPC1 cells, with or without 
gemcitabine treatment. This was done to investigate, if the knockdown of Lepr in AsPC1 cells, affected the 
chemo-sensitivity of AsPC1 cells to gemcitabine. 
 
 
 
 
 
 
 
Fig. 32: Proliferation and viability of nc and Lepr kd AsPC1 cells. NC and Lepr kd AsPC1 cells were treated with 
gemcitabine a) Proliferation measured by BrDU assay b) Viability measured by CCK-8. Experiment performed along 
with Eveline Molocea. 
 
 
As can be seen in Fig. 32, there was no consistent or significant effect of Lepr kd on the viability or 
proliferation of AsPC1 cells, when treated with ACM/FCM from 3T3-L1 cells, and gemcitabine. 
 
As we previously observed that the knockdown of Lepr was unstable with continuous passaging of cells, 
we decided to pharmacologically inhibit Lepr using an antibody against it, and treat cells with primary 
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adipocyte conditioned media. The primary ACM was used as a source of leptin. This would enable us to 
evaluate if inhibition of the Lepr affects their proliferation and viability when treated with gemcitabine. 
 
2.5.7 Pharmacological inhibition of LEPR in human PDAC cell lines does not affect their viability 
and proliferation upon gemcitabine treatment.  
 
 
We identified that lentiviral knockdown of LEPR was not very stable after routine culturing. After a few 
passages, the cells regained their Lepr mRNA expression. Therefore, in order to achieve a more stable 
inhibition of the LEPR, we pharmacologically inhibited the Lepr using anti-Lepr antibody. This antibody 
had 10-fold higher specificity for the human LEPR, therefore we performed our assays with human PDAC 
cell lines.  
 
We isolated primary subcutaneous iWAT from C57BL/6J mice, separated the stromal vascular fraction 
(SVF) from the tissue explant, and differentiated them to adipocytes using the standard differentiation 
cocktail. The differentiated primary cells were then serum starved on day 10 of differentiation for 4 hours, 
and the supernatant was collected and used as the ACM for this experiment. The ACM was used as a 
source of leptin, and either LEPR specific antibody or isotype specific control antibody was added, to 
evaluate if inhibition of the LEPR affected the sensitivity of human PDAC cell lines- Capan1 and AsPC1, to 
gemcitabine. 
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Fig. 33: Effect of LEPR/control antibody treatment on Capan1 and AsPc1 proliferation. Capan1 and AsPC1 cells 
were treated with LEPR Ab or control Ab, and primary adipocyte or fibroblast conditioned media from mouse SC 
WAT. They were treated with or without gemcitabine and proliferation was measured by BrDU assay.  
 
 
Anti-LEPR Ab treatment did not have significantly different effect on proliferation upon gemcitabine 
treatment, compared to control Ab treatment (Fig. 35). 
 
So far, we performed all our experiments of Lepr kd cells and gemcitabine treatment, in an in vitro setting. 
However, going forward, we wanted to investigate the in vivo chemo-sensitivity of Panc02 - wt and Lepr 
kd tumors to gemcitabine.  
 
2.5.8 Progression and chemo-sensitivity of subcutaneous Panc02 tumors with Lepr 
knockdown in wt mice 
 
In order to investigate the effect of knockdown of Lepr on in vivo tumor progression and chemo-
sensitivity to gemcitabine, we implanted wt and Lepr knockdown Panc02 cells in C57BL6/J mice. The 
kd cells were generated by pooling lentivirus infected Panc02 cells, that showed lowest Lepr 
expression on qPCR. 
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Fig. 34: Progression of SC Panc02 tumors transfected with shnc or shLepr in C57BL6/N mice.  a) Tumor growth 
comparison between NC and Lepr kd tumors with and without gemcitabine treatment b) Tumor weight comparison 
between NC and Lepr kd tumors, with and without gemcitabine treatment.   
 
 
 
The Lepr kd tumors grew larger than the control tumors. Also initially the Lepr kd tumors treated with 
gemcitabine, grew significantly larger than control tumors treated with gemcitabine. However, by the 
end of the experiment the gemcitabine groups had similar tumor volumes. The tumor mass was 
measured after sacrificing the mice. The Lepr kd tumors were significantly heavier than the control 
tumors. However, there was no significant difference in tumor mass between the kd and control 
tumors treated with gemcitabine (Fig. 34). This prompted us to confirm the Lepr expression in the in 
vivo tumor samples by qPCR. 
 
2.5.9 qPCR analysis from in vivo tumor samples revealed the loss of Lepr kd status  
 
As we did not find differences in the tumor volumes between control and Lepr kd tumors, we 
measured the mRNA expression levels of Lepr from the in vivo tumors, by qPCR.  
 
 
 
 
Fig. 35: Relative mRNA expression for Lepr from in vivo Panc02 tumors . n=3, means ±SEM, * indicates 
significance 
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As can be seen in Fig. 37, the expression level of Lepr was similar in the control and Lepr kd Panc02 
tumors-, without gemcitabine. Therefore, in the vehicle treated mice, the Lepr kd tumors regained 
their Lepr mRNA expression during the course of tumor progression. However, in the gemcitabine 
treated group, the Lepr knockdown tumors showed significantly lower receptor expression levels 
compared to the control tumors. For reasons unknown, gemcitabine treatment significantly 
increased the expression of Lepr mRNA in both the Lepr kd and control tumors, compared to the 
respective PBS treated mice (Fig. 35). 
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3 DISCUSSION 
 
3.1 Adipocyte conditioned media provides pro-tumorigenic signals to PDAC 
 
It is well known that obesity is associated with the hypertrophic expansion of white adipocytes, and alters 
the secretion of adipokines, contributes to insulin resistance, and creates a chronic inflammatory state in 
the adipose tissue. The increased secretion of pro-inflammatory adipokines has been shown to favor 
tumors of several types including, prostate, colorectal, and breast carcinomas [62].  
 
We investigated the effects of adipocyte conditioned media on PDAC progression. For this, we used 
immortalized murine 3T3-L1 cells as an in vitro model of adipocytes. 3T3-L1 cells are routinely used as an 
in vitro model for studying adipogenesis. Originally generated by the clonal expansion of rodent cells, 3T3-
L1 cells serve as a cost-effective alternative to using primary mouse adipocytes [69]. Upon treating PDAC 
cell lines with conditioned media from mature 3T3-L1 adipocytes, we observed strong pro-tumorigenic 
effects in vitro. We observed that the ACM from 3T3-L1 cells promotes proliferation, migration, and 
invasion of several PDAC cell lines that we examined. Also, the tumor promoting effects were specific to 
conditioned media from differentiated 3T3-L1 adipocytes, and not observed with fibroblast conditioned 
media. This indicates that the pro-tumorigenic effects were mediated by differentiated 3T3-L1 adipocytes, 
and not fibroblasts.  
 
Moreover, we demonstrated that the migration inducing effect of the 3T3-L1 ACM on BxPC3 cells, was 
significantly blunted upon heat inactivation of the ACM. We reasoned that the effects were lost because 
of heat-induced denaturation of secreted protein factors present in the ACM. This led to our hypothesis 
that secreted adipokines from 3T3-L1 adipocytes mediate pro-tumorigenic effects on PDAC cells. 
However, heat-denaturation could also have an impact on the metabolite fraction of ACM. Therefore, we 
cannot rule out the contribution of metabolites secreted from 3T3-L1 adipocytes, which could potentially 
mediate pro-tumorigenic effects as well.  
 
The tumor micro-environment influences the tumor proliferation, and invasion [70]. The characteristics 
of the malignant tumors are not just affected by their self-autonomous signaling, but also by paracrine 
and endocrine effects mediated by secreted soluble factors from the surrounding stromal cells [70]. 
Adipose tissue is linked to breast cancer tumorigenesis, as it is the most abundant component of the 
stroma in the breast tissue [71]. Conditioned media from 3T3-L1 adipocytes was shown to promote 
proliferation, and reduce apoptosis in breast cancer cell lines [70]. The adipocytes in close proximity to 
the tumors, often display modified characteristics like delipidation, and are called the cancer associated 
adipocytes (CAAs). The CAAs communicate with tumor cells through pro-inflammatory molecules, 
proteases etc. to promote tumor proliferation and invasiveness [72], [73]. 
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Although the link between adipocytes and other cancer entities have been studied, there is not much 
literature on role of adipocytes in PDAC progression [74]. Recently, it was shown that 3T3-L1 adipocytes 
rescue the proliferation of murine PDAC/PanIN cells specifically under nutrient/glutamine deprived 
growth conditions, by secreting glutamine [74]. This study identifies glutamine transfer as a potential 
mechanism linking adipocytes to the proliferation of PDAC/PanIN cells [74]. 
 
3.2 Obesity leads to higher pancreatic tumor burden in distinct mouse models of 
metabolic dysregulation 
 
Considering the global obesity pandemic, there is an urgent need to decipher the fundamental 
mechanisms linking obesity to tumorigenesis. BMI, and adiposity affect malignancies in a sex-dependent, 
and tumor site-specific manner [75]. Several mechanisms including the insulin and insulin-like growth 
factor-Iaxis, sex steroids, and adipokines, have been proposed to mediate the effects of obesity on 
malignant tumor progression [75]. Firstly, hyperinsulinemia associated with obesity, reduces the levels of 
IGF binding proteins -1 and -2 (IGFBP-1 and IGFBP-2, which under normal circumstances bind and inhibit 
the action of IGF-I), resulting in higher levels of free and biologically active IGF-I which promotes 
tumorigenesis [75]. Secondly, higher aromatase activity in the adipose tissue of obese post-menopausal 
women, has been associated with augmented conversion of androgenic precursors to estrogen, and 
estrogen is well known for its pro-tumorigenic effects on breast cancer [76], [77]. Lastly, dysregulated 
adipokine secretion by the adipose tissue in obesity, mediates tumor promoting effects. For e.g., the 
adipokine leptin is pro-inflammatory, and is significantly upregulated in obesity, and promotes growth of 
hematopoietic cells, and normal and transformed epithelial tissue, and promotes angiogenesis [78]. On 
the other hand, obesity induced reduction in the levels of the insulin sensitizing adipokine: adiponectin, 
promotes insulin resistance. Epidemiological studies indicate an inverse correlation between circulating 
adiponectin concentration and the incidence of breast, endometrial, and prostate cancer [75], [79], [80], 
[81], [82], [83]. 
 
Several researchers have tried to investigate the link between obesity and PDAC, however the underlying 
mechanisms involved are largely unknown. PDAC is known to be an aggressive malignancy characterized 
by desmoplastic stromal response, and resistance to known chemotherapeutics [35], [84], [85]. 
Inflammation plays a critical role in the initiation and progression of PDAC. Chronic inflammation 
mediated by pancreatitis, obesity, and multiple genetic and environmental factors support PDAC 
development [46].    
 
Studies have showed that obesity leads to intra-pancreatic fat infiltration, which increases the incidence 
of pre-cancerous PanIN lesions [45]. Augmented adipose tissue hypoxia during obesity could also play a 
role in promoting metastasis and angiogenesis in PDAC tumors [61]. Adipose tissue is an important 
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component of the PDAC tumor micro-environment. Visceral adipose tissue is predominantly associated 
with obesity induced metabolic dysregulation. Recently, it was shown that a high-fat and high-calorie 
(HFHC) diet induces inflammation specifically in the peri-pancreatic adipose tissue of KrasG12D (KC) 
mouse model of PDAC, compared to KC mice on a low calorie diet [86]. This observation was supported 
by the presence of higher inflammatory foci, smaller sized adipocytes, and an altered cytokine expression 
in the inflamed peri-pancreatic adipose tissue of the HFHC fed KC mice [86]. Others have shown using an 
acinar cell specific model of oncogenic Kras, that High-fat diet (HFD) provides the external inflammatory 
stimulus for the activation of oncogenic Kras signaling which drives the progression of PanIN lesions to 
PDAC [48].  
 
Interestingly, calorie restriction (CR) in mouse models transplanted with PDAC cells, reduces murine and 
human PDAC tumor growth, NF-B activation, and downregulates pro-tumorigenic signaling in the 
tumors, in an insulin like growth factor-1 (IGF-1) dependent manner [87]. The beneficial effects of CR were 
further elaborated in spontaneous PDAC development, where CR in comparison to HFD, reduces PDAC 
desmoplasia and metastasis, and prolongs tumor free survival in KrasInk4a+/- mice, through reduced IGF-
1 and Akt/mTOR signaling [88]. Therefore, CR  plays a beneficial role in delaying the progression of PanIN 
lesions to PDAC by modulating IGF-1 signaling and reducing inflammation [87], [88].  
 
We hypothesized that obesity accelerates PDAC progression, and that the transcriptional 
dysregulation/absence of Tblr1 in the mouse adipose tissue is an underlying mechanism linking obesity 
and PDAC tumorigenesis. The ATKO (Adipocyte tissue specific KnockOut of Tblr1) mice were previously 
shown by our group, to have dysregulated adipose tissue metabolism, impaired lipolysis, and hypertrophic 
adipocytes [58]. These mice were also shown to gain a higher body weight upon high fat feeding, 
compared to control mice [58]. In line with our hypothesis, we demonstrated that subcutaneous Panc02 
tumors grew significantly larger in both male and female ATKO mice, compared to the control mice. 
However, examination of the tumors did not reveal any differences in the histological features, or gene 
expression patterns. Also, in vitro exposure of PDAC cell lines to Tblr1 kd ACM did not have any significant 
impact on tumor cell viability and proliferation, compared to the control CM. Therefore, with our current 
results we could not conclude that higher tumor volumes observed in the ATKO mice, was due to the 
absence of Tblr1 alone. We concluded that the higher tumor burden in the ATKO mice could be an 
implication of the overall systemic effects of increased adiposity, and dysregulated adipose tissue 
metabolism in the ATKO mice.  
 
We further demonstrated that tumor xenografts of murine Panc02 cells grow significantly larger in distinct 
congenital mouse models of obesity and MetS, i.e. db/db and ob/ob mice. Mouse models with loss-of-
function mutation for leptin or LEPR, i.e. ob/ob and db/db mice, proceed to develop defective whole body 
energy metabolism reflected as obesity, diabetes, infertility, and immune dysfunction [89], [90]. The 
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above results from tumor implantation studies in ATKO, db/db, and ob/ob mice point to the conclusion 
that obesity indeed accelerates PDAC growth, and increases tumor burden in mouse models of metabolic 
dysfunction.  
 
3.3 Leptin promotes chemo-resistance of PDAC cells to gemcitabine in vitro 
 
Adipose tissue is no more considered merely as an energy storing organ, but as an active endocrine tissue 
secreting several bioactive factors called adipokines. Adipokines mediate the paracrine and endocrine 
action of adipose tissue on other organs to maintain overall energy homeostasis. Under healthy 
conditions, there is a balance between pro- and anti-inflammatory adipokines. However, under conditions 
of metabolic dysfunction or obesity, the balance is tilted towards pro-inflammatory cytokines, which leads 
to immune cell infiltration, and activation of pro-inflammatory M1 macrophages within the adipose tissue. 
All the above factors alter the tumor micro-environment, and provide potential tumor promoting signals. 
 
Our efforts to identify secreted factors from dysfunctional adipose tissue, mediating pro-tumorigenic 
effects, led us to investigate the role of leptin. We identified leptin to be significantly upregulated in the 
iWAT of db/db mice, with subcutaneous Panc02 tumors. Interestingly, the Panc02 tumors grew 
significantly larger in these db/db mice, compared to wt mice.  
 
Leptin is a 16 kDa polypeptide, which is the most abundant adipokine secreted by the adipose tissue. It is 
mainly involved in regulating appetite and whole body energy metabolism through its action on 
hypothalamic neurons. Obesity is associated with significant upregulation in the circulating levels of 
leptin, both in humans, as well as in mouse models of obesity. Leptin has been associated with the 
development of several malignancies, mainly via the JAK/STAT pathway upstream of PI3K/AKT3 signaling, 
and ERK1/2 signaling [91]. It has been reported that leptin expression goes up under hypoxic conditions, 
which often exists within solid tumors [92], [93]. Leptin has been linked to angiogenesis, and vascular 
remodeling in breast cancer [94].  
 
The role of leptin in PDAC progression is controversial. It has been shown that leptin increases the 
invasiveness and metastasis of PDAC by upregulation of MMP-13 [95]. However, others showed that 
plasma leptin concentrations in newly diagnosed PDAC patients is significantly lower than in control 
subjects [96].  
 
Gemcitabine is the standard mono-therapy for treating advanced PDAC with a response rate of less than 
20% [97]. However, only recently in 2010, a new drug combination called FOLFIRINOX (FFX) was 
introduced for the clinical treatment of metastatic pancreatic cancer [98]. FFX consists of a combination 
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of chemotherapeutics including oxaliplatin, irinotecan, and 5-fluorouracil [98]. Chemo-resistance to 
standard chemotherapeutics is a major concern in the treatment of PDAC. Understanding the factors that 
promote chemo-resistance in PDAC would be instrumental in improving the existing treatment options 
for PDAC. Although, leptin signaling has been reported to play a role in tumor chemo-resistance, its role 
in PDAC chemo-resistance is not well understood. It has been demonstrated that a high expression of Lepr 
in glioblastoma is associated with increased tumor chemo-resistance to temozolomide [99]. Increased 
LEPR expression has been linked to enrichment of glioblastoma cells with stemmness markers, and it was 
proposed that the SOX-2/OCT4 signaling downstream to the STAT3 pathway maintains the stemness in 
LEPR positive cells, which modulates the chemo-resistance of glioblastoma to temozolomide [99]. 
Expression of LEP in gastro-oesophageal adenocarcinomas was shown to be associated with resistance to 
cisplatin and radiological treatment, and the pharmacological inhibition of LEPR improved sensitivity to 
cisplatin in highly drug-resistant glioblastoma cells [100].  
  
Upon treating murine and human PDAC cell lines with recombinant leptin, we observed an increase in 
their viability in vitro. However, we could not demonstrate that this chemo-resistance was mediated 
through Lepr signaling because of the following observations: Firstly, there was no difference in the 
proliferation, and viability of wt and Lepr kd PDAC cells (Panc02, and AsPC1) when treated with 
gemcitabine. Secondly, subcutaneous Panc02 tumors generated by injecting wt and Lepr kd cells into wt 
mice, responded similarly to gemcitabine treatment in vivo. qPCR analysis confirmed that Lepr expression 
was restored in the kd tumors. We reasoned that the restoration of Lepr mRNA expression in the kd 
tumors must be beneficial to tumor growth, which could potentially promote the elimination of Lepr kd 
cells from the tumor. Also, we made an interesting observation that gemcitabine treatment increased the 
Lepr mRNA expression in both wt and Lepr kd cells. The effect of gemcitabine treatment on Lepr 
expression in PDAC cells needs further investigation. Finally, pharmacological inhibition of Lepr in Panc02 
cells by anti-Lepr antibody did not enhance the chemo-resistance of human PDAC cells (Capan1, and 
AsPC1) towards gemcitabine. In conclusion, our results indicate that the effect of leptin on PDAC chemo-
resistance is not consistent between in vitro and in vivo experimental systems, and further research is 
required in this regard, perhaps utilizing orthotopic tumor mouse models, to clearly understand the role 
of leptin in PDAC progression and chemo-sensitivity. 
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3.4 Outlook and summary  
 
In summary our data shows that adipocyte conditioned media increases the proliferation, migration, and 
invasion of PDAC cell lines in vitro, and subcutaneous PDAC tumors grow significantly larger in mouse 
models of metabolic syndrome. In order to evaluate if there are stronger tumor promoting effects of 
dysregulated adipocyte conditioned media on PDAC cell lines, it would be critical to perform trans-well 
assays of PDAC cell lines with primary adipose tissue conditioned media from wt/obese/high fat fed mice. 
So far, we did not treat mature 3T3-L1 adipocytes with inflammatory cytokines like TNF etc., which could 
potentially mimic the dysregulated and inflammatory state of the adipose tissue in an in vitro setting. The 
above experiments could elucidate if conditioned media from dysregulated adipose tissue, generated 
from primary or from TNF treated 3T3-L1 adipocytes, further accelerates PDAC tumorigenesis in vitro, 
compared to the conditioned media from lean/healthy adipose tissue. 
 
Going forward, it is important to identify if the tumor inducing effects from the adipocyte conditioned 
media are mediated by secreted protein factors, or by metabolites like fatty acids etc. released by the 
adipocytes. We previously exposed the conditioned media from 3T3-L1 cells to high temperature in order 
to heat inactivate the proteins. However, this procedure can potentially alter the integrity of some 
metabolites as well. Hence, it would be crucial to separate the proteins from the conditioned media using 
a milder procedure, like molecular weight cut-off filters. Culturing PDAC cell lines with such protein free 
ACM would clearly indicate if the secreted proteins are indeed mediating the observed pro-tumorigenic 
effects.  
 
A comparative secretome analysis between lean and obese WAT would help in identifying potential 
differentially secreted candidates mediating pro-tumorigenic effects on PDAC progression. To this end, 
either primary SVF (stromal vascular fraction) differentiated to WAT in vitro, or mature primary adipocytes 
embedded in a collagen matrix could be employed. In addition, such analysis can be extended to different 
WAT depots, i.e. – visceral and subcutaneous WAT. Such an analysis would be instrumental in identifying 
secreted proteins, particularly from obese WAT that promote PDAC progression, and if they are 
differentially regulated in distinct WAT depots. 
 
Finally, it is important to test and validate the effects of the identified secreted protein candidates using 
in vivo mouse models of PDAC. Although, tumor xenograft models are very useful for understanding tumor 
progression, they are not representative of the tumor micro-environment associated with PDAC. Hence, 
it would be necessary to orthotopically implant PDAC cells into mice, and evaluate the interaction 
between potential adipose tissue secreted factors and tumor progression. The schematic below depicts 
some of our key findings and the future prospects (Fig. 36).  
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Fig. 36: Schematic representing current findings and future prospects:  3T3-L1 adipocyte conditioned media 
significantly increased proliferation, viability, migration, and invasion of PDAC cells in vitro. Panc02 xenografts grew 
significantly larger in distinct mouse models of obesity (db/db, and ob/ob mice). This led to the hypothesis that 
adipocyte secreted factors mediate PDAC progression. In future, these results must be validates using primary mouse 
ACM from wt mice and obese mice (ob/db/HFD-fed mice). Following this, comparative secretome analysis would help 
identify differentially regulated adipokines between wt and obese abdominal WAT (aWAT). Finally, the effects of 
identified candidates need to be validated in orthotopic mouse models of PDAC.
METHODS 53 | P a g e  
 
 
 
4 METHODS 
4.1 Molecular Biology 
 
Transformation of E.coli 
 
TOP10 competent E.coli strain was transformed by chemical transformation. 50 µl of cell suspension was 
thawed on ice and mixed with 0.1-1 µg of plasmid DNA. After 30 min incubation on ice, a heat shock at 
42°C was applied for 30 s. Afterwards, 250 µl of SOC medium was added and cells were incubated at 37°C 
under vigorous shaking, and were subsequently plated onto LB agar plates containing the appropriate 
antibiotic. 
 
Bacterial liquid cultures 
 
Single colonies were inoculated into LB medium supplemented with the appropriate antibiotic. Depending 
on the amount of DNA needed, 2-200 ml cultures were inoculated. The cultures were incubated over night 
at 37°C under vigorous shaking (~160 rpm). 
 
Preparation of plasmid DNA from E.coli 
 
Plasmid DNA was isolated from E.coli bacterial cultures using commercially available kits, following the 
manufacturer’s instructions (QIAprep Plasmid Miniprep Kit, Qiagen for small scale plasmid preparation; 
PureLink HiPure Plasmid Maxiprep Kit, Invitrogen for large scale plasmid preparation). 
 
PCR 
 
DNA from plasmids, cDNA or a genomic DNA was amplified by polymerase chain reactions using a 
thermocycler (PTC 200) and Phusion polymerase (Finnzymes). The primers used are listed in the material 
section. PCR reactions were set up following the manufacturer’s instructions and were programmed 
according to the Tm of each individual primer pair and the length of the PCR product.   
 
RNA isolation 
 
A) From PDAC cell lines/3T3-L1 adipocytes 
 
Cells were harvested in 1 ml QIAzol (Qiagen) and transferred to RNase free tubes. Lysates were incubated 
at room temperature for 5 min to release nucleoprotein complexes before adding 200 μl of chloroform. 
Mixtures were vortexed for 15 secs and then centrifuged for 30 min at 13,000 rpm, 4°C. The upper 
aqueous solution containing the RNA was transferred into a fresh reaction tube. The RNA phase was then 
mixed with equal volume of isopropanol and incubated at room temperature for 10 min, followed by a 
METHODS 54 | P a g e  
 
 
 
10 min centrifugation step at 13,000 rpm, 4°C. The supernatant was aspirated and the pellet was washed 
once with 1 ml of 75% ethanol. The pellet was dried until translucent at RT and re-solubilized in 30 µl 
DNase/RNase free water. The samples were stored at -80°C until further use. 
 
C) From frozen tissue 
 
Frozen tissue samples were transferred into a 2 ml RNase/DNase-free reaction tube containing 1 ml 
QIAzol (Qiagen) and a pre-cooled stainless steel beads. The samples were lysed using the TissueLyser 
for 90 secs at a frequency of 30 Hz. Lysates were incubated at room temperature for 5 min to release 
nucleoprotein complexes before adding 200 μl of chloroform. Phase separation was performed as 
described in A). The upper phase was then transferred to a new tube containing 1 volume 100 % ethanol 
to precipitate nucleic acids. RNA was then purified using the RNeasy micro kit (Qiagen), following the 
manufacturer’s instructions. RNA was eluted in 50 µl DNase/RNase free H2O and stored at -80°C until 
further use. 
 
Determination of RNA concentration 
 
The RNA concentrations were measured using the NanoDrop ND- 1000 spectrophotometer. 1 uL of 
sample was placed on the sample holder and concentration was determined by spectrophotometric 
measurement at 260nm. Simultaneously, the absorbance ratio of 260 nm/280 nm was measured to 
assess sample contamination with protein. 
 
cDNA synthesis 
 
Complementary DNA was synthesized using the Fermentas cDNA synthesis kit, following the 
manufacturer’s protocol. 200-1000 ng of RNA was used as the starting material, and the reverse 
transcription reaction was run in the thermocycler. Finally, the cDNA was diluted 10 fold in DNase/RNase 
free water and stored away at -20°C until further use.   
 
Quantitative PCR 
 
5 µl of the diluted cDNA samples obtained from reverse transcription were used for quantitative PCR. A 
master mix was prepared containing 10 µl TaqMan Gene Expression Assay Supermix, 4.5 µl DNase/RNase 
free water and 0.5 µl TaqMan probe per individual reaction. Technical triplicates of all samples were 
included. The TaqMan probes used were obtained from Applied Biosystems or MWG and are listed in the 
material section. Water was used as a negative control and samples containing no reverse 
transcriptase served as controls for genomic DNA contamination. 20 µl PCR reactions were transferred 
per well onto a MicroAmp Optical 96 well reaction plate and quantitative PCR was performed using the 
StepOnePlus Real Time PCR System (Applied Biosystems). 
 
METHODS 55 | P a g e  
 
 
 
Gene expression profiling 
 
Gene expression profiling was performed in tumor samples from wt and ATKO SC Panc02 tumors, or from 
the subcutaneous inguinal WAT of wt and db/db mice with Panc02 tumors. RNA isolation, cRNA 
synthesis and hybridization to Mouse Genome 430 2.0 arrays (Affymetrix, Freiburg) were performed 
according to the manufacturer’s recommendations. Three arrays per sample were hybridized. CustomCDF 
by Brainarray with Entrez based gene definitions (Entrez basic version 13) was used to annotate the arrays 
(Sandberg R., 2007). The raw fluorescence intensity values were normalized applying quantile 
normalization. Differential gene expression was analyzed based on ANOVA using a commercial software 
package (SAS JMP8 Genomics, version 4, SAS Institute, Cary, NC). A false positive rate of a=0.05 with FDR 
correction was taken as the level of significance. Pathways belonging to various cell functions were 
obtained from public external databases (KEGG, http://www.genome.jp/kegg/). A Fisher's exact test was 
performed to detect the significantly regulated pathways. 
 
4.2 Cell Biology 
 
All experiments with eukaryotic cells were performed under sterile conditions. Cells were cultivated at 
37°C, 5% CO2 and 95% humidity. All media and additives were warmed to 37°C prior to use. A list of the 
media used for cell culture experiments is shown in Tab. 5. 
 
Name Medium Serum Antibiotic Further Additives 
3T3L1 culture DMEM (1g/L glucose) 10% FBS 1% P/S - 
3T3L1 Differentiation DMEM (4.5 g/L glucose) 10% FBS 1% P/S See Tab. 6 
3T3L1 virus infection DMEM 1g/L glucose - - - 
Freeze medium DMEM (4.5 g/L glucose) 20% FBS - 10% DMSO 
HEK293 culture DMEM (4.5 g/L glucose) 10% FBS 1% P/S  
Primary adipocyte culture DMEM 10% FBS 1% P/S - 
Primary adipocyte 
differentiation 
DMEM 5% FBS 1% P/S See Tab. 6 
All PDAC cell line culturing DMEM (4.5 g/L glucose) 10% FBS 1% P/S - 
 
Tab. 2: Media used for cell culture and virus experiments. 
 
 
Thawing cells 
 
Eukaryotic cells were stored in liquid nitrogen tanks in 1 ml aliquots containing 1 X 106 cells in freeze 
medium. Following thawing at 37°C, the suspension was added to 9 mL of DMEM with 10% FBS and 1% 
P/S (complete media), centrifuged at 2000 rpm for 3 mins to remove DMSO. The supernatant was 
aspirated and the pellet was re-suspended in 1 mL of complete media and added to 19 mL of complete 
media on a 15 cm cell culture dish. 
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Freezing cells 
 
Eukaryotic cells were trypsinized and resuspended in freezing medium containing 20% FBS and 10% 
sterile DMSO. The cells were counted and diluted to 1X106 cells/ml, and aliquoted in cryotubes as 1 
mL aliquots in the freezing medium. The aliquots were placed in Mr. Frosty boxes, filled with 
isopropanol, for a gradual cooling, in -80 degree freezer for overnight. Next day, the cells were 
transferred to liquid N2 storage. 
 
Cultivation of 3T3-L1 fibroblasts 
 
3T3-L1 cells were cultivated on 15 cm tissue culture plates in 20 ml 3T3-L1 culture medium. Cells were 
never allowed to grow beyond 70% confluency, and a passage of 15 was never exceeded to avoid 
diminished differentiation capacity. For passaging, the cells were first washed in 1x PBS and trypsinized, 
then the detached cells were re-suspended in 10 ml of fresh medium. Cells were pelleted by centrifugation 
at 2000 rpm for 3 min and subsequently re-suspended in 10 ml fresh medium. After manual counting in a 
Neubauer counting chamber, 4x 104 cells were plated onto a 15 cm tissue culture dish containing 20 ml 
medium. Cells were passaged every 3-4 days. 
 
Differentiation of 3T3-L1 fibroblasts into adipocytes 
 
3T3-L1 fibroblasts were differentiated into adipocytes by the addition of insulin, 3-isobutyl-1- 
methylxanthine (IBMX), dexamethasone (Dex), and ABP (L-ascorbate, d-biotin, pantothenic acid). Cells 
were cultivated on 10 cm plates until they reached confluency and then induced to undergo differentiation 
by adding 3T3-L1 differentiation media as shown in Tab. 6. 
 
Differentiation Medium Additives 
Day 1 3T3-L1 differentiation 1 g/ml insulin 
0.25 M Dexamethasone 
0.5 mM IBMX 
1/1000 ABP stock solution 
Day 3 3T3-L1 differentiation 1 g/ml insulin 
0.25 M Dexamethasone 
0.5 mM IBMX 
1/1000 ABP stock solution 
Day 5 3T3-L1 differentiation 1 g/ml insulin 
1/1000 ABP stock solution 
Day 8 3T3L1 culture None 
 
Tab. 3. Media and additives for differentiation of 3T3-L1 fibroblasts. 
 
Experiments could be performed 8-12 days after initiation of differentiation. 
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Cultivation of mouse and human pancreatic cancer cell lines 
 
The pancreatic cancer cell lines were usually split twice a week, on Mondays and Fridays, as they grew 
and reached confluence very fast. All cells were grown in DMEM High glucose media with 10% FBS and 
1% Penstrep. Following was the split ratio for the most commonly used PDAC cell lines: 
 
Cell line Splitting ratio Approx. volume of addition from 
10 mL suspension 
Panc02 1:50 200 l 
Capan1 1:5 2 ml 
Panc8680 1:20 500 l 
BxPC3 1:10 2 ml 
AsPC1 1:5 2 ml 
 
Tab. 4. Culturing conditions for PDAC cell lines. 
 
Cultivation of human embryonic kidney (HEK) cells 
 
HEK293 and HEK293A cells were cultured in HEK293 and HEK293A culture medium, respectively. The cells 
were cultivated either in 10 cm tissue culture plates containing 10 ml medium or in 15 cm plates with 25 
ml medium. Cells were passaged at 70-90% confluency by re-suspension in 10 ml fresh medium, 
centrifugation (3 min, 2000 rpm), re-suspension of the pelleted cells in 10 ml medium and subsequent 
addition of the twentieth part of the cells to a new tissue culture plate. Cell number could be 
determined by using the Neubauer counting chamber. 
 
Transfection with Lipofectamine 2000 
 
For   higher   transfection   efficiency   HEK293   cells   were   transfected   with   Lipofectamine   2000 
transfection reagent (Invitrogen). 3 µl of the reagent was added to 250 µl of serum free Opti-MEM 
medium. The mixture was combined with DNA which was diluted in the same medium, and the mixture 
was incubated in RT for 20 min to allow complex formation. The DNA/Lipofectamine complex was added 
dropwise to cells in antibiotic-free medium. Medium change to the normal culture medium was 
performed the following day. 
 
Isolation of preadipocytes from adipose tissue 
 
Preadipocytes were isolated from the stromal vascular fraction (SVF) of abdominal or inguinal white 
adipose tissue or from interscapular brown adipose tissue depots of male C57Bl6/N mice aged 6-9 weeks. 
Mice were sacrificed by cervical dislocation, sterilized with 70% ethanol and adipose tissue depots were 
dissected. After cleaning the fat pads, the pads were chopped until no pieces could be observed anymore 
and subsequently digested in 7 ml collagenase medium (DMEM containing 1.5 mg/ml type II collagenase 
and 0.5% BSA) for 1 h at 37°C and 180 rpm. To stop the reaction, 6 ml culture medium was added and 
adipocytes floated to the top of the tube, where they could be removed. If needed, 1 ml QIAzol reagent 
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(Qiagen) was added to 200 µl mature adipocytes to isolate RNA as described. The SVF was harvested by 
centrifugation at 1000 rpm, 10 min. The cell pellet was resuspended in culture medium, filtered through 
a 70 µm falcon strainer, and cells were plated to 12 well plates. One mouse harvested one 12 well plate 
abdominal preadipocytes, one 12 well plate inguinal preadipocytes, and half a 12 well plate brown 
preadipocytes. Cells were washed every day with warm culture medium until they reached confluency. 
 
Differentiation of primary preadipocytes into adipocytes 
 
Primary preadipocytes are differentiated into adipocytes by the addition of insulin, 3-isobutyl-1- 
methylxanthine (IBMX), dexamethasone and ABP (L-ascorbate, d-biotin, pantothenic acid). In case of 
preadipocytes harvested from brown adipose tissue, in addition triiodothyronine (T3) is added. 
Preadipocytes were cultivated until they reached confluency (approximately 1 week) and then induced to 
undergo differentiation by adding primary cell differentiation media as shown in Tab. 8. 
 
Differentiation Medium Additives 
Day 1 Primary adipocyte differentiation 1 g/ml insulin 
0.25 M Dexamethasone 
1/1000 ABP stock solution 
(3nM T3) 
Day 3 Primary adipocyte differentiation 1 g/ml insulin 
0.25 M Dexamethasone 
1/1000 ABP stock solution 
(3nM T3) 
Day 5 Primary adipocyte differentiation 1 g/ml insulin 
1/1000 ABP stock solution 
 
Day 8 Primary adipocyte culture none 
Tab. 5: Media and additives for differentiation of primary adipocytes. 
 
Experiments could be performed 8-12 days after initiation of differentiation. 
 
Adenovirus harvest 
 
Adenoviruses were harvested when 70-80% of the HEK293A cells were rounded and lost adhesion. For 
that purpose, the remaining adherent cells were rinsed off the tissue culture plate with a pipette and 
transferred to a centrifuge tube together with the non-adherent cells. Cells were pelleted by 
centrifugation (2000 rpm, 10 min, RT) and resuspended in 0.5-3 ml PBS-TOSH. The cell suspension was 
stored at -80°C. For cell disruption and virus release, 3 freeze-and-thaw cycles were performed. To this 
end the suspension was frozen in liquid nitrogen, thawed at 37°C and vortexed vigorously. Cell debris 
was removed by centrifugation at 3000 rpm for 5 min and the resulting crude virus lysate could be purified 
by CsCl gradient or used for further infection of HEK293A cells. 
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Adenovirus purification using cesium chloride gradient 
 
Cesium chloride (CsCl) gradient centrifugation is a type of density gradient centrifugation for the 
purification of viral particles (Green et al. 2006). Confluent HEK293A on twenty 15 cm cell culture dishes 
were infected with crude virus lysate or purified adenovirus (1 µl per plate) and grown until 70-80% of 
the cells were rounded and lost adhesion, then they were harvested and lysed as described. PBS-TOSH 
was added to the crude lysate to a final volume of 20 ml. All solutions were adjusted to pH 7.2. The first 
gradient was layered with 9 ml 4.4 M CsCl, 9 ml 2.2 M CsCl and 20 ml virus in PBS-TOSH. After 
ultracentrifugation (2 hrs., 4 °C, 24,000 rpm, SW28 rotor) the virus band was removed and added to the 
same volume saturated CsCl. The second gradient was layered with 8 ml virus in CsCl, 1.5 ml 4.4 M CsCl 
und 1.5 ml 2.2 M CsCl. Following the second ultracentrifugation (3 hrs., 4 °C, 35,000 rpm, SW40Ti rotor) 
the virus band was removed in the smallest possible volume and dialyzed against PBS-glycerol over night 
at 4°C. 10% glycerol was added to the purified virus and aliquots were stored at -80°C. 
 
Virus Titration using the Tissue Culture Infectious Dose 50 (TCID50) method 
 
The virus titer (plaque forming units, pfu) could be determined by TCID50. For that purpose, 10,000 
HEK293A cells were seeded in 100 µl virus titration medium in each well of a 96 well plate and infected 
with decreasing amounts of virus after 2 hrs. of adhesion. Serial dilutions of the virus up to 10-14   were 
prepared in titration medium and added to the cells.  Double measurements were performed for each 
virus.  10-12 days after infection and incubation at 37°C the plaques were counted and the titer was 
calculated using the following formula: 
 
T = 10 1+(s-0.5) x 10 pfu / ml 
 
(s = sum of positive wells starting from the 10-1 dilution; 10 positive wells per dilution = 1) 
 
Transduction of 3T3-L1 fibroblasts with adenoviruses 
 
2x 104  3T3-L1 cells were seeded on 6 well plates and transduced with different amounts of adenovirus 72 
hrs. after plating. MOIs of 100 to 100,000 were tested, with MOI 1000 being ideal for efficient 
transduction of the fibroblasts. The desired amounts of virus were diluted in low glucose DMEM without 
FCS and 0.5 µg/ml poly-L-lysin were added (Orlicky et al. 2001). After incubation at RT for 60-100 min the 
mixture was added to PBS-washed cells. After 90 min incubation at 37°C, 3T3-L1 culture medium was 
added and cells were incubated 72-96 hrs. until harvest. In case of subsequent differentiation, the 
differentiation process was started 24 hrs. after virus transduction. 
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Transduction of 3T3-L1 adipocytes with adenoviruses 
 
Differentiated 3T3-L1 adipocytes on day 10 of differentiation were washed with PBS and trypsinized. The 
pelleted cells were then resuspended in 3T3-L1 culture medium and filtered through a 70 µM falcon 
strainer. Cells were counted, and 4 x 105 cells were plated to each well of a 12 well plate. For larger scale 
transductions, 4.8 x 106 cells were plated on 10 cm plates. 24 hrs later, floating cells were removed by 
washing with PBS and 3T3-L1 starve 1 medium was added. After 12 hrs incubation, cells were again 
washed in PBS and 3T3-L1 starve 2 medium was added for 12 hrs. Adenoviruses at an MOI of 500 were 
diluted in 3T3-L1 virus infection medium containing 0.5 µg/ml poly-L-lysin (250 µl medium per well or 2.5 
ml per 10 cm plate). After incubation at RT for 60-100 min the mixture was added to PBS-washed cells. 
After 90 min incubation at 37°C, 3 volumes 3T3-L1 culture medium were added and cells were incubated 
72-96 hrs until harvest. 
 
Generation of lentivirus in HEK293T cells 
 
Day 1: Seed HEK293T cells in 6-well plates (106 cells/well), in low antibiotic medium (High glucose, 10% 
FBS, P/S 1:1000, 2 ml/well), so that they are 60-80% confluent the following day. 
 
Day 2: Mix 
Solution a) 200l Opti-MEM + 5ml lipofectamine 2000, incubate for 5 mins at RT 
Solution b) pLKO1 1g 
                    psPAX2 1g 
                    pMD2.G 100ng 
in 200l Opti-MEM 
Note: make master mix for packaging plasmids psPAX2 and pMD2.G and add different pLKO1 vectors 
afterwards. 
- combine solutions and incubate 20-30 mins at RT 
- change medium on HEK293T cells to 1.5 ml medium with low antibiotics 
- dropwise add transfection-DNA mixture 
 
Day 3: In the morning, change medium to high BSA medium (DMEM high glucose, 10% FBS + 1.1 g/100 
ml supplemental BSA) 
 
Day 4: Next day in the evening, collect virus, freeze at -80°C in aliquots  
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Transduction of PDAC cell lines with lentivirus 
 
Day1: Plate 3 x 104 cells/well, on a 6-well plate (multiple plates, one plate for each virus), also include 
control wells without any virus  
Day 2: Remove media and add virus + polybrene + media mixture to cells (different amounts, to choose 
the best one later) 
 
Component Volume (l) Volume (l) Volume (l) 
Virus 50 l 100 l 200 l 
Polybrene (1:1000) 1.5 l  1.5 l  1.5 l 
Media 1448.5 l 1398.5 l 1298.5 l 
Total 1500 l 1500 l 1500 l 
 
Tab. 6: Composition of transduction mix for infecting PDAC cells with lentivirus. 
 
Day 3: In the morning, change media to low antibiotics media (DMEM high glucose, 10% FBS, 1:1000 P/S) 
 
Day 4: Add fresh media with 1 g/mL puromycin (stock puromycin: 10 mg/ml) 
 
Day 5/6: Check for confluence, if there are too many cells, then trypsinize each well individually and re-
plate with 1 g/ml of puromycin containing media. 
 
Day 8: Select for puromycin resistant cells. Many cells would float, and only infected cells would survive 
with puromycin.  
 
Select and re-plate 2 x 96-well plates/virus (1 cell/well) and change media every 2-3 days. Allow for colony 
formation, and once the colonies are big enough, select 5 wells/virus and grow them in larger 10 cm 
dishes, and confirm knockdown by qPCR. Finally, after confirmation of target knockdown, freeze away the 
cells in liquid N2 for long-term storage. 
 
CCK-8 Cell viability Assay 
 
10uL of CCK-8 reagent was added to 100uL of media on top the cells in 96-well plates. The plate was 
incubated for 30 mins and 1 hr in the cell culture incubator and the absorbance was measured at 450nm. 
 
Trans-well migration assay 
 
Panc02/Capan1/BxPC3/Panc8680 cells were seeded onto the migration inserts in 24 well plates supplied 
by BD Falcon. Following assay conditions were used for specific cell lines as mentioned below: 
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S.No. Cell line Assay Seeding density Seeding Vol. Chemoattractant vol. 
1 Panc02 Migration 10,000 100 l 1 ml 
2 Panc02 Invasion 40,000 100 l 1 ml 
3 Panc8680 Migration 20,000 100 l 1 ml 
4 Capan1 Migration 100,000 100 l 1 ml 
5 BxPC3 Migration 40,000 100 l 1 ml 
      
Tab. 7: Migration and invasion assay conditions and seeding densities for different PDAC cell lines. 
 
Cells were always seeded in serum free medium on the top chambers, and chemoattractant (Conditioned 
media/ Complete media with 10% FBS) was added to the bottom chambers. The plates were incubated 
overnight in the cell culture incubator. The next morning, the inserts were removed one by one, the media 
was aspirated, and the inside was wiped with a dry qTip, followed by a wet qTip (soaked in water). 
Following this, the inserts were fixed in methanol for 10 minutes. Afterwards, they were quickly in DPBS, 
and stained in 0.01% crystal violet (in water) solution for 15 mins. The inserts were washed thrice in water. 
All these solutions were pre-dispensed in 24 well plates. Finally, the inserts were inverted and carefully 
excised using a scalpel, and placed on top of mounting media on a glass slide. A cover slip was carefully 
placed on top of the inserts. The migrating or invading cells were manually counted, by taking images of 
3-4 fields per insert. 
 
Trans-well invasion assay 
 
The invasion inserts were equilibrated for 45 mins in the cell culture incubator, with some DPBS on over 
the insert, and some in the bottom of the inserts. The DPBS, was removed and Panc02/Capan1 cells were 
seeded onto the invasion inserts, coated with matrigel, in 24 well plates, supplied by BD Falcon. 
Chemoattractant solution (Conditioned media/ Complete media) was added to the well bottom. The 
plates were incubated overnight in the cell culture incubator. The next morning, the inserts were removed 
one by one, the inside was wiped with a dry qTip, then with a wet qTip, and incubated for 10 mins in 
methanol, followed by quick wash in DPBS, then a 15 min incubation in 0,01% Crystal violet solution in 
water (filtered), and washed thrice in water. All these solutions are pre-dispensed in 24 well plates. Finally, 
the inserts are inverted and carefully cut out using a scalpel, and placed on a drop of mounting media on 
a glass slide. The migrating or invading cells are manually counted, by taking images of 3-4 fields per 
condition. 
 
BrDU Proliferation Assay 
 
BrDU assay was performed to measure proliferating cells. The BrDU kit from Cell Signaling was used and 
the assay was performed using manufacturer’s protocol. Tumor cells were plated on 96-well black plates 
with transparent bottom, treated with leptin or gemcitabine or both for specific periods before they 
performing BrDU assay on them. Following are the cell densities used for different cell lines for BrDU 
assay. 
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Cell line Cell density for  
BrDU assay 
Time of incubation  
before assay 
Panc02  4000                                                72 hours 
Capan1  10000 72 hours 
Panc8680   5000 72 hours 
BxPC3  10000 72 hours 
AsPC1  10000 72 hours 
 
Tab. 8: BrDU assay conditions and seeding densities for different PDAC cell lines. 
 
4.3 Animal experiments 
 
The animals were housed according to international standard conditions with a 12 hrs dark, 12 hrs light 
cycle and regular unrestricted diet if not stated otherwise. Animal handling and experimentation was 
performed in accordance with NIH guidelines and approved by local authorities (Regierungspräsidium 
Karlsruhe). Blood was taken after cervical dislocation. Tissues including tumors, and fat pads were 
collected, weighed, snap-frozen in liquid nitrogen and used for further analysis. 
 
Obesity models 
 
8-12 week old ob/ob, or db/db mice were obtained from Charles River Laboratories (Brussels, BEL) and 
maintained on a 12 hrs light-dark cycle with regular unrestricted diet. All mice were procured from Jackson 
labs. Following are the ordering details: 
db/db mice: B6.BKS. (D)-Leprdb/J (#000697) 
ob/ob mice: B6.Cg-Lepob/J (#000632 
wt control mice: C57BL/6J (#000664) 
 
Mice for SC tumor implantation 
 
Male wt C57Bl6/J purchased from Charles River or C57Bl6/J mice from Barrier 2 within DKFZ at the age of 
6-8 weeks were used for SC Panc02 tumor implantations. 
 
Mice for isolation of primary preadipocytes 
 
Male wt C57Bl6/J purchased from Charles River at the age of 6-9 weeks were used for the isolation of 
primary preadipocytes. 
 
Adipocyte specific TBLR1 knockout mice 
 
Adipocyte specific TBLR1 knockout mice were generated on C57Bl6 background (C57BL/6- 
Tbl1xr1(tm2273Arte) Tg(Fabp4-Cre)1Rev) by TaconicArtemis as described in ‘Results’. Adipocyte specific 
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knockout was assessed by Southern Blot in various tissues with probes created by primers shown in 
‘Materials’. 
 
Body composition analysis using Echo MRI  
 
Mice were weighed and body composition was determined using magnetic resonance (Echo MRI, 
Echo Medical Systems, Houston). 
 
Blood serum 
 
Blood serum was obtained by incubation of blood samples at room temperature for 30 min and 
subsequent centrifugation for 1 hr at 3,000 rpm, 4°C. The serum (upper phase) was transferred to a new 
tube and stored at -80°C. 
 
Tumor luminescence measurement and imaging using IVIS 
 
The IVIS (In Vivo Imaging System) was used to measure luminescence signal from luciferase expressing 
subcutaneous Panc02 tumors. The C57Bl6/J mice with tumors were gently shaved a day prior to imaging 
to prevent high background signal from black fur. On the day of imaging, the computer was turned on, 
and the camera was allowed to cool after opening the imaging software. The isoflurane level was visually 
checked and if less, was filled manually. The pump and oxygen supply were turned on. The mice were 
intraperitoneally injected with 10 l/g of luciferase solution from a stock solution of 15mg/ml. They were 
placed in an anesthetizing chamber with 3% vaporized isoflurane for few minutes until unconscious. At 
any given point of time, only three mice could be imaged simultaneously, so they were staggered and 
treatment groups were measured side by side for comparison. They were carefully placed with the tumors 
facing up, inside the imaging chambers and the isoflurane level was reduced to 1%. Even while imaging, 
the mice were remained anesthetized as they were placed adjacent to nozzles supplying 1% isoflurane. 
Luminescence signal was measured and it was a direct measure of the tumor size. The instrument’s 
camera needed time to cool down, and always stayed on as per manufacturer’s instruction. 
 
Glucose tolerance test 
 
In a glucose tolerance test, glucose is injected in the peritoneum of fasted mice and blood samples are 
taken to determine how quickly the sugar can be cleared from the blood. Improved insulin signaling results 
in lower glucose levels as the sugar load induces a better clearance from the blood stream. Mice were 
fasted for 16 hrs prior to the experiment. The animals were transferred into fresh cages equipped with 
fresh water but no food. The following morning, the body weight and the initial blood glucose levels were 
determined by nicking the tail with a razor blade. Blood glucose was measured using a glucometer strip. 
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10 μl/g body weight of a 20% glucose solution were then injected intraperitoneally. Blood glucose was 
measured before injection and 20, 60, and 120 min after injection. 
 
4.4 Biochemistry 
 
Preparation of protein extracts 
 
Cell lysis using RIPA Buffer 
 
Cells were washed once with PBS, followed by addition of RIPA buffer supplemented with protease and 
phosphatase inhibitor. The plates were placed on ice for 30 minutes to promote complete lysis. Then the 
cells were scraped with a cell scraper and transferred to Eppendorf tubes. For viscous cell lysates, 
sonication was performed additionally to completely lyse the cells. Then, an appropriate volume of 2 x 
SDS sample buffer was added and the samples were boiled for 10 min at 95°C and stored at -20°C until 
further use. 
 
Protein extracts from tissue samples 
 
Protein extracts from tissue samples were prepared using the Tissue Lyser. Frozen tissue pieces or powder 
were transferred to 2 ml safe lock tubes containing ice-cold protein lysis buffer A containing protease and 
phosphatase inhibitors and a pre-cooled steel bead. The samples were immediately homogenized using 
the Tissue Lyser for 2 min at 30 Hz. The extracts were incubated on a rotating wheel for 1 hour and then 
transferred to fresh tubes (if using adipose tissues, the fat remains in the old tube). Then, extracts were 
supplemented with high salt supplement buffer and incubated for an additional hour on the wheel at 4°C. 
The protein concentration was determined using the BCA kit (Pierce) and samples were diluted in 5x SDS 
sample buffer and boiled for 10 min at 95°C. 
 
Determination of Protein Concentration 
 
Protein concentrations were determined using the BCA kit (Pierce) following the manufacturer’s 
instructions. If SDS concentration of the samples was higher than 0.1 %, protein concentration had to be 
determined using the 2D-Quant kit (Amersham Biosciences) following the manufacturer’s instructions. All 
measurements were performed in duplicates within the linear range of the BSA standard curves (0.1-2 
mg/ml). 
 
SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Immunoblotting 
 
Protein samples in SDS sample buffer were loaded onto 6-12 % SDS-polyacrylamide gels and blotted onto 
nitrocellulose membranes using a wet blot system. Blotting was performed at 80 V for 70 minutes or 30 
V overnight in transfer buffer. Membranes were subsequently blocked by incubation in 5% milk or 5% BSA 
dissolved in PBS-T/TBS-T for 1 hour. Primary antibodies diluted in 5 % milk, were incubated with the 
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membranes overnight at 4°C. The membranes were washed with PBS-T/TBS-T, the next day and incubated 
with the secondary antibody conjugated to horse radish peroxidase (HRP) at a dilution of 1:5000 for 1 hr. 
To detect specific bands, the enhanced chemiluminescence system (ECL) Western Blotting Detection 
Reagent was applied. The chemiluminescent signal produced by the blots was detected with the 
ChemiDoc detector (BioRad). Exposure times differed based on the quality of specific antibodies and 
protein concentrations. The results were quantified using the Image Lab software. 
 
Determination of Free Fatty Acid Levels 
 
Free Fatty Acids were determined in serum samples or cell supernatants using a colorimetric assay from 
WAKO (NEFA kit) following the manufacturer’s instructions. 4 µl of serum samples or 20 µl of cell 
supernatants were measured in duplicates. A standard curve was determined using a dilution series of 
oleic acid. OD-values were determined at 540 nm. 
 
Determination of Glycerol Levels 
 
Glycerol content of serum or cell supernatants was measured using a calorimetric assay. The Free Glycerol 
component of the serum TG determination kit from Sigma was used for this assay. 4 µl of serum or 20 µl 
of supernatants were transferred to a 96well plate, 100 µl Free Glycerol Reagent were added and glycerol 
levels were measured at 540 nm against a glycerol standard. 
 
Determination of Triglyceride Levels 
 
TG levels were determined by separating TGs into one glycerol and three fatty acid molecules and 
measuring the glycerol using a colorimetric assay. The serum TG determination kit from Sigma was used 
for this assay. 4 μl of isolated hepatic TG, 4 μl of serum or 20 µl of cell supernatants were transferred to 
a 96well plate. In order to determine a blank value, 100 μl Free Glycerol Reagent were added to each well 
and the plate was incubated at 37°C for 5 min. Free glycerol levels were measured at 540 nm. In a second 
reaction (assay), 100 μl TG Reagent were added. This mixture contains the enzyme lipase, which catalyzes 
the release of fatty acids from TGs. Plates were incubated at 37°C for 5 min and measured at 540 nm. TG 
content (TG-bound glycerol) was determined by subtracting the free glycerol (blank) from the second 
measurement of total glycerol (assay). 
 
Determination of Blood Glucose Levels 
 
Blood glucose levels were determined using a drop of blood obtained from the tail vein and an automatic 
glucose monitor (One Touch, Lifescan). 
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4.5 Statistical Analysis 
 
Statistical analyses were performed in GraphPad Prism 7 software, using a 1- or 2-way ANOVA (analysis 
of variance) with Bonferroni-adjusted post-tests, or t-test with one-factorial designs, respectively. A p 
value of < 0.05 was considered statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001. 
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5 MATERIAL 
5.1 Instruments and equipment 
 
Instrument/Equipment Model Company 
Aspiration adaptor, 8-channel Heraeus Function Neolab (Heidelberg, Germany) 
Bacterial Incubator Line ThermoFisher Scientific (Schwerte, 
Germany) 
Bacterial shaking incubator Multitron 
Standard 
Infors HT (Bottmingen, Switzerland 
Balance EW 2200-NM Kern and Sohn (Balingen, Germany) 
Bunsen Burner Labogaz 206 Campingaz (Hattersheim, Germany) 
Cell counter, automated CountessTM Life TechnologiesTM, InvitrogenTM 
(Darmstadt, Germany) 
Cell culture hood Cellgard Class II 
Biological safety 
cabinet 
IBS Integrad Biosciences (Fernwald, 
Germany) 
CO2 incubator  Sanyo (Etten Leur, The Netherlands) 
Counting chamber BLAUBRAND®, 
Neubauer 
improved, Cat. 
No. 717805 
Brand (Wertheim, Germany) 
Digital Caliper  Bochem (Weilburg, Germany) 
Echo MRITM Whole Body 
Composition Analyser 
 Echo medical systems (Housten, TX, USA) 
Fluorescence lamp for 
microscope 
HXP 120C Carl Zeiss (Oberkochen, Germany) 
Fluorometer QubitR 2.0 Life TechnologiesTM, InvitrogenTM 
(Darmstadt, Germany) 
Freezer (-200C)  Liebherr (Biberach, Germany) 
Freezer, ultra-low temperature 
(-800C) 
New Brunswick 
U101 Innova 
Eppendorf (Hamburg, Germany) 
Freezing Container Mr. FrostyTM, 
5100-0001 
ThermoFisher Scientific (Schwerte, 
Germany) 
Gas anaesthesia system XGI-8 Caliper Lifesciences (Rodgau, Germany) 
Glucometer OneTouchR Ultra Lifescan (Neckargemünd, Germany) 
Immunoblot documentation ChemiDocTM   
XRS+Molecular 
Imager® with 
ImageLabTM 
Software 
Biorad (München, Germany) 
IVISR Optical Imaging System Lumina II Caliper LifeSciences (Rodgau, Germany) 
LED Fluorescence Lamp for 
Axio Imager.M2 
Colibri.2 Carl Zeiss (Oberkochen, Germany) 
Magnetic stirrer MR 30001 K Heidolph (Schwabach, Germany) 
Magnetic stirrer Duomax 1030 Heidolph (Schwabach, Germany) 
Magnetic stirrer 444-7076 VWR (Darmstadt, Germany) 
Microscope Axio ImagerM.2 
with AxioCam 
HRc 
Carl Zeiss (Oberkochen, Germany) 
Microscope Axiovert 40 CFL 
with AxioCam 
ICm1 
Carl Zeiss (Oberkochen, Germany) 
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Instrument/Equipment Model Company 
Microscope, automated Olympus Cell^R Olympus (Hamburg, Germany) 
Microplate reader Mithras LB 940 Berthold Technologies (Bad Wildbad, 
Germany) 
Microplate reader, Varioscan 
LUX  
Multimode ThermoFisher Scientific (Schwerte, 
Germany) 
Micropipette 0.2-2 l P2 Gilson (Limburg.Offheim, Germany) 
Micropipette 1-10 l P10 Gilson (Limburg.Offheim, Germany) 
Micropipette 2-20 l P20 Gilson (Limburg.Offheim, Germany) 
Micropipette 10-100 l P100 N Gilson (Limburg.Offheim, Germany) 
Micropipette 50-200 l P200 Gilson (Limburg.Offheim, Germany) 
Micropipette 100-200 l P1000 Gilson (Limburg.Offheim, Germany) 
Micropipette, 8-channel, 0.5-
10 l 
Research plus Eppendorf (Hamburg, Germany) 
Micropipette, 8-channel, 10-
100 l 
Research Eppendorf (Hamburg, Germany) 
Microtome RM2245 Leica (Wetzlar, Germany) 
Microwave 700 W Severin (Sundern, Germany) 
Mouse cage system Green Line IVC 
SealSafePlus 
Tecniplast (Hohenpeißenberg, Germany) 
Mouse housing cabinet, 
ventilated 
 Tecniplast (Hohenpeißenberg, Germany) 
Mutistep pipette Multipette® plus Eppendorf (Hamburg, Germany) 
Mutistep pipette Multipette® M4 Eppendorf (Hamburg, Germany) 
Nanodrop ND-1000 ThermoFisher Scientific (Schwerte, 
Germany) 
Orbital shaker Duomax 1030 Heidolph (Schwabach, Germany) 
pH meter Qph 70 GHM Messtech, Greisinger (Regenstauf, 
Germany) 
Pipetboy  acu Integra (Fernwald, Germany) 
Power supply for gel 
electrophoresis 
PowerPac BasicTM Bio-Rad (München, Germany) 
Power supply for Axio 
ImagerM.2 
232 Carl Zeiss (Oberkochen, Germany) 
Precision Balance M-power AZ124 Sartorius (Göttingen, Germany) 
Real-time PCR system StepOnePlus Life TechnologiesTM, InvitrogenTM 
(Darmstadt, Germany) 
Refrigerator (2-8 °C)  Liebherr (Biberach, Germany) 
Rotating Wheel  Neolab (Heidelberg, Germany) 
Sonicator Bioruptor® Plus Diagenode (Seraing, Belgium) 
Tabletop centrifuge Mikro 22R Hettich (Newport Pagnell, United Kingdom) 
Tabletop centrifuge Heraeus Fresco 
17 
ThermoFisher Scientific (Schwerte, 
Germany) 
Tabletop centrifuge Heraeus Biofuge 
pico 
ThermoFisher Scientific (Schwerte, 
Germany) 
   
Tabletop centrifuge Heraeus Biofuge 
primo 
ThermoFisher Scientific (Schwerte, 
Germany) 
Thermomixer Comfort Eppendorf (Hamburg, Germany) 
Thermocycler T3000 Biometra (Göttingen, Germany) 
Tissue grinder (all-glass) Dounce 7 mL Kimble Chase (Meiningen, Germany) 
Tissue Lyser MM 400 Retsch (Hahn, Germany) 
Titer plate shaker  ThermoFisher Scientific (Schwerte, 
Germany) 
Vortex mixer Genie Scientific Industries (Bohemia, NY, USA) 
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Instrument/Equipment Model Company 
Water bath  P-D Industriegessellschaft (Dresden, 
Germany) 
Water filter system TKA xCAD ThermoFisher Scientific (Schwerte, 
Germany) 
5.2 Consumables 
 
  
Product Company Cat. No. 
Cell scraper Corning (Wiesbaden, Germany) 3010 
Chamber slide, 8-well, Nunc-
Lab-Tek 
ThermoFisher Scientific (Schwerte, Germany) 177445 
0.2 mL Combitips advanced® Eppendorf (Hamburg, Germany) 0030 
089.413 
0.5 mL Combitips advanced® Eppendorf (Hamburg, Germany) 0030 
089.421 
0.5 mL Combitips advanced®, 
sterile 
 0030 
089.634 
5 mL Combitips advanced® Eppendorf (Hamburg, Germany) 0030 
089.456 
5 mL Combitips advanced®, 
sterile 
Eppendorf (Hamburg, Germany) 0030 
089.669 
10 mL Combitips advanced® Eppendorf (Hamburg, Germany) 0030 
089.464 
10 mL Combitips advanced® Eppendorf (Hamburg, Germany) 0030 
089.667 
CountessTM cell counting 
chamber slides 
Life TechnologiesTM, InvitrogenTM (Darmstadt, 
Germany) 
C10283 
Cover slips 24X60 mm #1 Menzel (Braunschweig, Germany) BB024060A1 
2 mL cryogenic vials StarLab (Hamburg, Germany) E3110-6122 
1.5 mL DNA LoBind tubes Eppendorf (Hamburg, Germany) 0030 
108.051 
500 mL Filter system 0.22 um, 
polystyrene, nonpyrogenic 
Corning (Wiesbaden, Germany) 430758 
10 uL filter tip, graduated StarLab (Hamburg, Germany) S1121-3810 
20 uL filter tip, graduated StarLab (Hamburg, Germany) S1120-1810 
100 uL filter tip, graduated StarLab (Hamburg, Germany) S1120-1840 
200 uL filter tip, graduated StarLab (Hamburg, Germany) S1120-8810 
1000 uL filter tip, graduated StarLab (Hamburg, Germany) S1126-7810 
Folded filters Munktell (Bärenstein, Germany) 4.303.280 
Genechip® Mouse Genome 
430 2.0 Array  
Affymetrix (High Wycombe, United Kingdom) 900496 
Glucose test strips, One 
Touch® Ultra  
Lifescan (Neckargemünd, Germany) - 
Histology casettes NeoLab (Heidelberg, Germany) 7-0014 
Imaging plate, 96-well clear 
bottom black wall 
BD FalconTM (Heidelberg, Germany) 353219  
Injection needle Sterican® 0.4 
X 20mm (27G) 
B.Braun (Melsungen, Germany) 4657705 
Inoculation loops 1 uL Sarstedt (Nümbrecht, Germany) 86.1567.050 
Insulin syringes, Micro-FineTM+ 
Demi, 0.3 mL 
BD Medical (Heidelberg, Germany) 324826 
MicroAmp® Optical Adhesive 
Film for qPCR 
LifeTechnologiesTM, Applied Biosystems® 
(Darmstadt, Germany) 
4311971 
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Product Company Cat. No. 
Microtiter plate, 96-well (Nunc 
F96) 
ThermoFisher Scientific (Schwerte, Germany) 260836 
Nitrocellulose membrane, 
Protran BA 85, 0.45 um 
GE Healthcare (Solingen, Germany) 10401196 
Parafilm® M Bemis® (Neenah WI, USA) PM-996 
Pasteur pipette, glass, long WU Mainz (Bamberg, Germany)  
PCR Tubes, 8 strips, 0.2 mL Greiner Bio-one (Frickenhausen, Germany) 673210 
PCR tube lids, flat, 8 strip Greiner Bio-one (Frickenhausen, Germany) 373250 
Petri dish for Agar plates Greiner Bio-one (Frickenhausen, Germany) 632180 
10 uL Pipette tip StarLab (Hamburg, Germany) S1111-3700 
200 uL Pipette tip Steinbrenner Laborsysteme (Wiesenbach, 
Germany) 
Tip-Tower 
Refill System 
1000 uL Pipette tip Steinbrenner Laborsysteme (Wiesenbach, 
Germany) 
Tip-Tower 
Refill System 
0.1 -10 uL pipette tips, ep 
T.I.P.S. ® LoRetention 
Eppendorf (Hamburg, Germany) 0030 
072.006  
0.5-20 uL pipette tips, ep 
T.I.P.S. ® LoRetention 
Eppendorf (Hamburg, Germany) 0030 
072.014 
1-200 uL pipette tips, ep 
T.I.P.S. ® LoRetention, 
Eppendorf (Hamburg, Germany) 0030 
072.022 
50-1000 uL pipette tips, ep 
T.I.P.S. ® LoRetention, 
Eppendorf (Hamburg, Germany) 0030 
072.030 
15 mL polypropylene 
centrifuge tubes 
Greiner Bio-one (Frickenhausen, Germany) 188271 
50 mL polypropylene 
centrifuge tubes 
Greiner Bio-one (Frickenhausen, Germany) 227261 
1.5 mL RNase-free centrifuge 
tubes, Multi® Safe Seal 
Carl Roth (Karlsruhe, Germany) AA80 
14 mL round- bottom snap-cap 
tubes, polypropylene 
BD FalconTM (Heidelberg, Germany) 352059 
1.5 mL safe-lock tube Eppendorf (Hamburg, Germany) 0030 
120.086 
2 mL safe-lock tube Eppendorf (Hamburg, Germany) 0030 
120.094 
5 mL safe-lock tube Eppendorf (Hamburg, Germany) 0030 
119.460 
Scalpel, disposable, sterile, No. 
21 
Feather (Osaka, Japan)  
5 mL serological pipettes BD FalconTM (Heidelberg, Germany) 357543 
10 mL serological pipettes BD FalconTM (Heidelberg, Germany) 357551 
25 mL serological pipettes BD FalconTM (Heidelberg, Germany) 357525 
50 mL serological pipettes BD FalconTM (Heidelberg, Germany) 357550 
5 mL skirted tube VWR (Darmstadt, Germany) 216-0153 
Stainless steel beads, 5 mm Qiagen (Hilden, Germany) 69989 
1 mL syringe, Soft-Ject® 
Tuberkulin 
Henke Sass Wolf (Tuttlingen, Germany) 5010-200V0 
5 mL syringe BD (Heidelberg, Germany) 309050 
20 mL syringe BD (Heidelberg, Germany) 300629 
50 mL syringe BD (Heidelberg, Germany) 300865 
10 cm tissue culture plate BD FalconTM (Heidelberg, Germany) 353003 
15 cm tissue culture plate BD FalconTM (Heidelberg, Germany) 353025 
Tissue culture plate, 6-well BD FalconTM (Heidelberg, Germany) 353046 
Tissue culture plate, 24-well BD FalconTM (Heidelberg, Germany) 353047 
Tissue culture plate, 48-well BD FalconTM (Heidelberg, Germany) 353230 
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Product Company Cat. No. 
Waste bags 200 X 300 mm Carl Roth (Karlsruhe, Germany) E706.1 
Weigh boats 41 X 41 mm Neolab (Heidelebrg, Germany) 1-1124 
Weigh boats 89 X 89 mm Neolab (Heidelebrg, Germany 1-1125 
WhatmanTM paper GE Healthcare (Solingen, Germany) 3030 917 
   
   
5.3 Kits 
 
Product Company Cat. No. 
   
BrDU Cell prliferation kit Cell Signaling Technology 6813S 
Click-iT® EdU Imaging Kit LifeTechnologiesTM, Applied Biosystems® 
(Darmstadt, Germany) 
C10338 
CCK-8 assay kit Sigma-Aldrich (München, Germany) 96992 
DNase Set, Rnase-free Qiagen (Hilden, Germany) 1023460 
Enhanced Chemiluminescence 
(ECL) kit 
Amersham Biosciences (Freiburg, Germany) - 
First strand cDNA synthesis kit, 
Fermentas 
ThermoFisher Scientific (Schwerte, Germany) K1612 
Glucose (HK) assay kit Sigma-Aldrich (München, Germany) GAHK20-1KT 
HR Series NEFA-HR (2) kit Wako Diagnostics (Neuss, Germany) 276-76491 
Pierce® BCA Protein assay kit ThermoFisher Scientific (Schwerte, Germany) 23225 
PureLink HiPure Plasmid 
Maxiprep kit 
LifeTechnologiesTM, InvitrogenTM (Darmstadt, 
Germany) 
K2100-06 
RNeasy® Mini Kit Qiagen (Hilden, Germany) 74106 
Serum Triglyceride 
determination kit 
Sigma-Aldrich (München, Germany) TR0100 
Superscript® Choice System for 
cDNA synthesis 
LifeTechnologiesTM, InvitrogenTM (Darmstadt, 
Germany) 
18090-019 
 
5.4 Enzymes 
 
Product Company Cat. No. 
Collagenase type I Sigma-Aldrich (München, Germany) - 
Proteinase K ThermoFisher Scientific (Schwerte, Germany) EO0491 
RNase A 10 mg/mL ThermoFisher Scientific (Schwerte, Germany) EN0531 
   
5.5 Plasmids 
 
Product Company Cat. No. 
Mission® shRNA Plasmid DNA, 
leptin receptor, mouse 
Sigma-Aldrich (München, Germany) SHCLND-NM_010704  
Mission® shRNA Plasmid DNA, 
leptin receptor, human 
Sigma-Aldrich (München, Germany) SHCLND-NM_002303 
pLKO.1-shRNA-scrambled Addgene (Cambridge, MA, USA) 1864 
pMD2.G Addgene (Cambridge, MA, USA) 12259 
psPAX2 Addgene (Cambridge, MA, USA) 12260 
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5.6 Chemicals and reagents 
 
Product Company Cat. No. 
Acetic acid  Sigma-Aldrich (München, Germany) 45731 
Acrylamide/bis-acrylamide 37.5:1, 
40% (Rotiphorese Gel 40 (37.5:1)) 
Carl Roth (Karlsruhe, Germany) T802.1 
Agarose Carl Roth (Karlsruhe, Germany) 3810 
Alexa Fluor 555, triethylammonium 
salt 
Life TechnologiesTM, Molecular Probes® 
(Darmstadt, Germany) 
A20012 
Ampicillin sodium salt Sigma-Aldrich (München, Germany) A9518 
Antibody diluent, Background 
reducing 
Dako (Hamburg, Germany) X0590 
APS (Ammonium persulfate) Carl Roth (Karlsruhe, Germany) 9592 
-Mercaptoethanol Sigma-Aldrich (München, Germany) M7154 
Biotin-blocking system (0.1% avidin 
solution and 0.01% biotin solution) 
Dako (Hamburg, Germany) X0590 
Boric acid (H3BO3) Sigma-Aldrich (München, Germany) 31146 
Bromophenol blue, sodium salt Sigma-Aldrich (München, Germany) 114405 
BSA for cell culture: Albumin 
solution from bovine serum, 30% 
DPBS, sterile-filtered 
Sigma-Aldrich (München, Germany) A9576 
BSA for immunoblotting and EdU 
assay: Albumin bovine Fraction V 
Biomol (Hamburg, Germany) 01400.100 
BSA fatty acid free Sigma-Aldrich (München, Germany) A8806 
CaCl2 (Calcium Chloride) Carl Roth (Karlsruhe, Germany) CN93 
Chloroform (CHCl3) Carl Roth (Karlsruhe, Germany) 3313 
CuSO4 (copper (II) sulfate 
petahydrate) 
Sigma-Aldrich (München, Germany) 209198 
DEPC (Diethylpyrocarbonate) Sigma-Aldrich (München, Germany) D5758 
DMEM High Glucose Pyruvate (+ L-
glutamine) 
Life TechnologiesTM, Gibco® (Darmstadt, 
Germany) 
41966-029 
DMEM Low Glucose Pyruvate (+ L-
glutamine) 
Life TechnologiesTM, Gibco® (Darmstadt, 
Germany) 
31885-023 
DMSO (Dimethylsulfoxide) sterile 
for cell culture 
Sigma-Aldrich (München, Germany) D2650 
DNA marker, Gene ruler, 100bp ThermoFisher Scientific (Schwerte, 
Germany) 
SM0241 
DPBS, no CaCl2, no MgCl2 Life TechnologiesTM, Gibco® (Darmstadt, 
Germany) 
14190-094 
DPBS 10x, no CaCl2, no MgCl2 Life TechnologiesTM, Gibco® (Darmstadt, 
Germany) 
14200-067 
DTT (Dithiothreitol) Applichem (Darmstadt, Germany) A2948 
EdU (5-ethynyl-2’-deoxyuridine) Life TechnologiesTM, Molecular Probes® 
(Darmstadt, Germany) 
A10044 
EGTA (Ethylene gycol-bis(2-
aminoethylether)-N,N,N‘,N‘-
tetraaceticacid 
Sigma-Aldrich (München, Germany) E4378 
Ethanol > 99.8 %, denatured with 
approx. 1% methyl ethyl ketone (for 
histology) 
Carl Roth (Karlsruhe, Germany) K928 
Ethanol, absolute Sigma-Aldrich (München, Germany) 32205 
Ethidium bromide solution, 1% / 10 
mg/mL 
Carl Roth (Karlsruhe, Germany) 2218 
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Product Company Cat. No. 
Fetal bovine serum (FBS), US origin Life TechnologiesTM, Gibco® (Darmstadt, 
Germany) 
26400-036 
Fluorescent mounting medium Dako (Hamburg, Germany) S3023 
Formaldehyde solution 37% J.T. Baker (Deventer, The Netherlands) 7040 
Formamide Merck KGaA, Calbiochem (Darmstadt, 
Germany) 
344206 
Gemcitabine 40 mg/mL HEXAL® - 
D-Glucose anhydrous Applichem (Darmstadt, Germany) A0883 
Glycerol Sigma-Aldrich (München, Germany) 15523 
Glycine Sigma-Aldrich (München, Germany) 33226 
HEPES Buffer solution, 1M Life TechnologiesTM, Gibco® (Darmstadt, 
Germany) 
15630-056 
H2O2 (Hydrogen peroxide) solution, 
30% 
Merck KGaA, Calbiochem (Darmstadt, 
Germany) 
1.07209 
HCl (Hydrochloric acid) 37% Sigma-Aldrich (München, Germany) 30721 
Hoechst 33342, trihydrochloride 
trihydrate, 10 mg/mL 
Life TechnologiesTM, Molecular Probes® 
(Darmstadt, Germany) 
H3570 
IBMX (Isobutyl methylxanthine) Sigma-Aldrich (München, Germany)  
IGEPAL® CA-630 (NP40 substitute) Sigma-Aldrich (München, Germany) 56741 
Imidazole Merck KGaA, Calbiochem (Darmstadt, 
Germany) 
4716 
Insulin human recombinant 
expressed in yeast 
Sigma-Aldrich (München, Germany) I2643 
Isoflurane Baxter (Unterschleißheim, Germany) I7403 
   
KCl (Potassium chloride) Carl Roth (Karlsruhe, Germany) A137 
KH2PO4 (Potassium dihydrogen 
phosphate) 
Carl Roth (Karlsruhe, Germany) 3904 
LB-Agar (Luria/Miller) Carl Roth (Karlsruhe, Germany) X969 
LB-Medium (Luria/Miller) Carl Roth (Karlsruhe, Germany) X968 
Lipofectamine® 2000 Transfection 
Reagent 
Life TechnologiesTM, InvitrogenTM 
(Darmstadt, Germany) 
11668-019 
Liquid DAB+ chromogen and 
substrate buffer 
Dako (Hamburg, Germany) K3468 
MgCl2.6H2O (magnesium chloride 
hexahydrate) 
Sigma-Aldrich (München, Germany) M9272 
MgSO4.7H2O (magnesium sulfate 
heptahydrate) 
Applichem (Darmstadt, Germany) A4101 
Milk powder, skim milk extra grade Gerbu (Heidelberg, Germany) 1602 
MOPS (3-(N-
morpholino)propanesulfonicacid 
Sigma-Aldrich (München, Germany) M3183 
Mouse recombinant leptin Peprotech  
Na2HPO4. 2H2O (di-sodium 
hydrogenphoshate dehydrate) 
Sigma-Aldrich (München, Germany) 30412 
Na3VO4 (sodium orthovanadate) Sigma-Aldrich (München, Germany) S6508 
NaCl (sodium chloride) Sigma-Aldrich (München, Germany) 31434 
NaF (sodium flouride) Sigma-Aldrich (München, Germany) S1504 
NaHCO3. 10H2O Merck KGaA, Calbiochem (Darmstadt, 
Germany) 
6391 
NaOH (sodium hydroxide) Sigma-Aldrich (München, Germany) 30620 
Opti-MEM® I Reduced Serum 
Medium 
Life TechnologiesTM, Gibco® (Darmstadt, 
Germany) 
31985-047 
PageRulerTM prestained protein 
ladder 
ThermoFisher Scientific (Schwerte, 
Germany) 
26616 
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Product Company Cat. No. 
Penicillin-streptomycin, liquid, 100x Life TechnologiesTM, Gibco® (Darmstadt, 
Germany) 
15140-122 
PMSF (phenylmethanesulfonyl 
fluoride) 
Sigma-Aldrich (München, Germany) P7626 
Polybrene (hexadimethrine 
bromide) 
Sigma-Aldrich (München, Germany) H9268 
Poly-L-Lysine hydrobromide Sigma-Aldrich (München, Germany) P2636 
Ponceau S solution 0.1% in 5% 
acetic acid 
Sigma-Aldrich (München, Germany) P7170 
Protease inhibitor cocktail Sigma-Aldrich (München, Germany) P8340 
Protease inhibitor cOmplete Roche (Mannheim, Germany) 04693116001 
Protease inhibitor cOmplete, EDTA 
free 
Roche (Mannheim, Germany) 04693132001 
Puromycin Sigma-Aldrich (München, Germany) P8833 
Pyruvate 100mM, 100x Life TechnologiesTM, Gibco® (Darmstadt, 
Germany) 
11360-039 
Qiazol lysis reagent Qiagen (Hilden, Germany)  
RiboLock Ribonuclease Inhibitor Fermentas, St. Leon Rot  
Roti®-Histofix 4% acetic acid free 
(pH 7.0), phosphate buffered 
formaldehyde solution 
Carl Roth (Karlsruhe, Germany) P087 
SDS (sodium dodecyl sulfate) Sigma-Aldrich (München, Germany) D6750 
Sodium acetate anhydrous Applichem (Darmstadt, Germany) A1522 
Sodium deoxycholate Sigma-Aldrich (München, Germany) D6750 
Standard chow diet Kliba Nafag (Kaiseraugst, Switzerland) 3437 
Sucrose Sigma-Aldrich (München, Germany) S1888 
Taqman® Gene Expression Master 
Mix 
Life TechnologiesTM, Applied Biosystems® 
(Darmstadt, Germany) 
4369016 
TEMED (N,N,N’,N’- 
teramethylethane-1,2-diamine) 
Carl Roth (Karlsruhe, Germany) 2367 
Tris 
(tris(hydroxymethyl)aminomethane) 
Sigma-Aldrich (München, Germany) T1503 
Triton® X-100 Applichem (Darmstadt, Germany) A1388 
Tryphan blue solution, 0.4% Life TechnologiesTM, InvitrogenTM 
(Darmstadt, Germany) 
T10282 
0.25% Trypsin-EDTA (1x), Phenol red Life TechnologiesTM, Gibco® (Darmstadt, 
Germany) 
25200-056 
Tween® 20 Sigma-Aldrich (München, Germany) P9416 
Water, nuclease free Life TechnologiesTM, Gibco® (Darmstadt, 
Germany) 
10977-035 
Xylene Merck KGaA, Calbiochem (Darmstadt, 
Germany) 
1.08681 
   
5.7 Antibodies 
 
5.7.1 Primary Antibodies 
Protein Company Cat. No. Origin 
AKT Cell Signaling 9272 rabbit 
-Actin Sigma A5441 mouse 
Caspase-3 Cell Signaling 9662 rabbit 
Cleaved Caspase-3  Cell Signaling 9664S rabbit 
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Protein Company Cat. No. Origin 
Cleaved PARP Cell Signaling 9544S mouse 
CyclinD1 Cell Signaling 2926 mouse 
Ki67 Dako M7279 mouse 
PARP Cell Signaling 9542 rabbit 
Phospho-AKT Cell Signaling 9271 rabbit 
Phospho-Histone H2A.X Cell Signaling 9718 rabbit 
Phospho-STAT3 Cell Signaling 9138S mouse 
p53 Cell Signaling 2524S mouse 
STAT3 Cell Signaling 12640S rabbit 
TBL1XR1 Novus Biologicals NB600-270 rabbit 
TBL1XR1 Abnova H00079718-M01 mouse 
-Actin Sigma A5441 mouse 
VCP Abcam 11433 Mouse 
    
    
5.7.2 Secondary Antibodies 
Protein Company Origin 
Anti-mouse IgG-HRP Bio-Rad, Munich  goat 
Anti-rabbit IgG-HRP Bio-Rad, Munich goat 
Anti-chicken IgG-HRP Chemicon, #AP162P rabbit 
Anti-goat IgG-HRP Sigma, #sc-2020 donkey 
 
 
5.8 Software 
 
Product Company 
AxioVision 
Graphpad Prism 7 
Zeiss 
GraphPad Software Inc., La Jolla, USA 
Inkscape Adobe 
ImageJ Freeware 
ImageLab Biorad 
Microsoft Office 
ND-1000 
Microsoft, Unterschleißheim 
Nanodrop 
Photoshop Adobe, San Jose, USA 
QuantityOne Bio-Rad, Munich 
StepOne Plus sytem Software  
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5.9 Solutions and Buffers 
 
All buffers were diluted in H20, unless otherwise stated. 
 
10X MOPS:   
200mM MOPS, 50mM NaAc, 10mM EDTA, pH 7.0 
 
10X PBS:   
1.4 M NaCl, 27 mM KCl, 100 mM Na2HPO4, 8 mM KH2PO4, 8 mM KH2PO4, pH 6.8 
 
2X SDS Sample Buffer 
120mM Tris/HCl pH 6.8, 4% SDS, 20% glycerol, 200 mM DTT, 0.01% bromophenol 
blue 
 
5X SDS Sample Buffer 
250 mM Tris/HCl pH 6.8, 0.5 M DTT, 10% SDS, 50% glycerol, 0.01% bromophenol blue 
 
ABP Stock 
50 mg/mL L-Ascorbate, 1 mM b-Biotin, 17 mM Pantothenic acid 
 
Blocking Buffer 
1x PBS, 0.1% Tween 20, 5% Milk powder 
 
Coomassie stain 
4 parts Coomassie Colloidal Blue, 1-part methanol 
 
Destain for Coomassie stained gels 
25% Isopropanol, 10% Acetic acid 
 
0.1% crystal Violet Solution 
1 mL of 2.3% stock crystal violet solution in 23 mL Milli Q H20 
 
RIPA Buffer 
50 mM Tris pH 8.0, 150 mM NaCl, 1% NP40, 0.5% SDS, 10% Sodium deoxycholate 
Always add protease and phosphatase inhibitors fresh, right before use 
 
Krebs-Ringer Buffer 
115 mM NaCl, 5.9 mM KCl, 1.2 mM NaH2PO4, 1.2 mM Na2SO4, 25 mM NaHCO3, Adjust 
pH to 7.4 
 
LB medium 
10 g/l Trypton, 5 g/l Yeast extract, 10 g/l NaCl, pH 7.0 
 
Oil Red O Stock 
0.7 g Oil Red O, 200 mL Isopropanol, Stirred Overnight, sterile filtered 
 
Oil Red O Working Solution 
6 parts Oil Red O Stock solution, 4 parts H2O 
 
PBS-T 
1x PBS with 0.1% Tween 20 
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SDS gel fixation buffer 
25% Isopropanol, 10% Acetic acid 
 
SDS running buffer (10x) 
0.25 M Tris, 1.92 M Glycin, 1% SDS 
 
TBE Buffer (10x) 
100 mM Tris, 1 mM EDTA, 90 mM Boric acid, pH 8.0 
 
TE Buffer 
1 mM EDTS, 10 mM Tris HCl, pH 8.0 
 
Transfer Buffer 
25 mM Tris, 192 mM Glycine, 20% Methanol, 0.01% SDS 
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6 APPENDIX 
6.1 Glossary 
 
Abbreviation Expansion 
ABD Abdominal 
ABP L-ascorbate, d-biotin, pantothenic acid 
ACM Adipocyte conditioned media 
ANGPT1 Angiopoietin 1 
AKT Protein kinase B (PKB) 
ANOVA Analysis of variance 
ATKO Adipocyte specific TBLR1 knockout 
BAT Brown adipose tissue 
BMI Basal metabolic index 
bp Base pairs 
BSA Bovine serum albumin 
BW Body weight 
cDNA Complementary DNA 
CM Conditioned media 
CNS Central nervous system 
Contrl Control 
DBD DNA binding domain 
Dex Dexamethasone 
DNA Deoxyribonucleic acid 
DTT Dithiothreitol 
FABP Fatty acid binding protein 
FBS Fetal bovine serum 
FCM Fibroblast conditioned media 
FFA Free fatty acid 
GC Gastronemius muscle 
GFP Green fluorescent protein 
H2AX H2A histone family, member X 
HDAC Histone deacetylase 
HDL High density lipoprotein 
HEK Human embryonic kidney 
HFD High fat diet 
IBMX 3-isobutyl-1-methylxanthine 
ING Inguinal 
Ifu Infectious units 
IL-6 Intereukin 6 
ip Intraperitoneal 
IR Insulin resistance 
IRS2 Insulin receptor substrate 
aWAT Abdominal white adipose tissue 
iWAT Inguinal white adipose tissue 
kd Knockdown 
kDa Kilo daltons 
LCN2 Lipocalin 2 
LBP Lipopolysaccharide binding protein 
LEP Leptin 
LEPR Leptin receptor 
LFD Low fat diet 
MetS Metabolic syndrome 
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Abbreviation Expansion 
MOI Multiplicity of infection 
mRNA Messenger RNA 
ml Milli liter 
mM Milli molar 
NEFA Non-esterified fatty acids 
nM Nano molar 
NR Nuclear receptor 
OD Optical density 
OE Overexpression 
p- Phospho- 
PDAC Pancreatic ductal adenocarcinoma 
p53 Tumor protein p53 
P/S Penicillin/Streptomycin 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PKA Protein kinase A 
PPAR Peroxisome proliferator-activated 
receptor gamma 
PPI Protein phosphatase inhibitor 
qPCR Quantitative polymerase chain reaction 
RNA Ribonucleic acid 
RXR Retinoic acid receptor 
SAA3 Serum amyloid A3 
SC Subcutaneous 
SEM Standard error of means 
shRNA Small hairpin RNA 
siRNA Small interfering RNA 
SVF Stromal vascular fraction 
TBL1 Transducin beta like 
TBLR1 Transducin beta like receptor 1 
TBP Thymine binding protein 
TG Triglyceride 
TNF Tumor necrosis factor a 
TZD Thiazolidinedione 
UCP1 Uncoupling protein 1 
VCP Valosin containing protein 
WAT White adipose tissue 
WHO World health organization 
wt Wild-type 
-AR Beta adrenergic receptor 
l Micro liter 
M Micro molar 
  
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6.2 Figures and tables 
6.2.1 Figures 
 
Figure  Title Page No. 
Fig. 1 Global database on Body Mass Index 2 
Fig. 2 Classification and functions of adipose tissue in humans and mice 3 
Fig. 3 Dysregulation of adipocytes in obesity 5 
Fig. 4 Cancer incidence in Germany 7 
Fig. 5 Cancer mortality in Germany 7 
Fig. 6 Mechanisms linking obesity and PDAC 10 
Fig. 7 Viability and proliferation time course assay of Panc02 with 3T3-L1 ACM 
and FCM 
13 
Fig. 8 Trans-well migration of Panc02, Panc8680, Capan1 and BxPC3 with 3T3-
L1 conditioned media 
15 
Fig. 9 Trans-well invasion of Panc02 with 3T3-L1 conditioned media 16 
Fig. 10 Body weight, blood glucose, and body composition measurements by 
ECHO MRI, for wt and ATKO mice 
18 
Fig. 11 IVIS measurement of tumor luminescence from male and female wt and 
ko mice bearing SC Panc02 tumors 
19 
Fig. 12 Tumor, ABD, and ING fat mass from wt and ATKO mice 20 
Fig. 13 TG measurement from SC tumors 21 
Fig. 14 H and E- staining of Panc02 SC tumor sections from wt and ATKO mice 22 
Fig. 15 Ki67 staining of SC Panc02 tumors from wt and ATKO mice 23 
Fig. 16 Heat map for Microarray samples from wt and ATKO SC Panc02 
tumors 
24 
Fig. 17 Adenovirus mediated knockdown of Tblr1 in 3T3-L1 adipocytes 25 
Fig. 18 Treatment of Panc02 cells with nc, or Tblr1 kd ACM from 3T3-L1 cells  26 
Fig. 19 Microarray from the WAT of wt and db/db, SC Panc02 tumor bearing 
mice 
27 
Fig. 20 qPCR data depicting the overexpression of candidate genes in HEK293A 
cells 
28 
Fig. 21 Trans-well migration of Panc02 with candidate overexpression-
conditioned media from HEK293A cells 
29 
Fig. 22 qPCR data showing the knockdown of candidate genes in mature 3T3-
L1 adipocytes 
30 
Fig. 23 Viability of Panc02 and BxPC3 with recombinant candidate proteins 31 
Fig. 24 Effect of recombinant LEP on BxPC3, and Panc8680 spheroid invasion 
through collagen I matrix 
33 
Fig. 25 Viability and chemo-resistance of PDAC cell lines after recombinant 
leptin treatment, measured by CCK-8 assay 
34 
Fig. 26 Experimental plan for study of SC Panc02 tumor progression and chemo-
sensitivity to gemcitabine in wt, ob/ob and db/db mice 
36 
Fig. 27 Progression of SC Panc02 tumors in wt, ob/ob, and db/db mice 37 
Fig. 28 Lentivirus mediated knockdown of Lepr in mouse PDAC cell line 
Panc02 
38 
Fig. 29 Lentivirus mediated knockdown of Lepr in mouse PDAC cell line 
Panc02 
39 
Fig. 30 Proliferation and viability of wt and Lepr kd Panc02 cells 40 
Fig. 31 Lentivirus mediated knockdown of Lepr in human PDAC cell line AsPC1 40 
Fig. 32 Proliferation and viability of nc and Lepr kd AsPC1 cells 41 
Fig. 33 Effect of anti-LEPR/control antibody treatment on Capan1 and AsPc1 
proliferation 
43 
Fig. 34 Progression of SC Panc02 tumors transfected with shnc or shLepr in 
C57BL6/N mice 
44 
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Figure  Title Page No. 
Fig. 35 Relative mRNA expression for Lepr from in vivo Panc02 tumors 44 
Fig. 36 Schematic representing current findings and future prospects 52 
 
6.2.2 Tables 
 
Table  
 
Title 
 
Page No. 
Table. 1 Types of pancreatic cancer neoplasms 8 
Table. 2 Media used for cell culture and virus experiments 55 
Table. 3 Media and additives for differentiation of 3T3-L1 fibroblasts 56 
Table. 4 Culturing conditions for PDAC cell lines 57 
Table. 5 Media and additives for differentiation of primary adipocytes 58 
Table. 6 Composition of transduction mix for infecting PDAC cells with lentivirus 61 
Table. 7 Migration and invasion assay conditions and seeding densities for 
different PDAC cell lines 
62 
Table. 8 BrDU assay conditions and seeding densities for different PDAC cell lines 63 
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